[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 227
1. Kume K, Murata I, Yoshikawa I, Yamasaki M, Kanda K, Otsuki M: Endoscopic piecemeal mucosal resection of large colorectal tumors. Hepatogastroenterology; 2005 Mar-Apr;52(62):429-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic piecemeal mucosal resection of large colorectal tumors.
  • BACKGROUND/AIMS: Since endoscopic en bloc resection of large and sessile tumors is technically difficult, endoscopic en bloc piecemeal mucosal resection (EPMR) is usually chosen for resection of such tumors.
  • Tumors resected by EPMR are, however, difficult to evaluate histologically.
  • METHODOLOGY: We removed 30 large colorectal tumors in 30 patients by EPMR between 1992-2000.
  • Patients in whom no residual tumor was found by both endoscopic and histologic examination were considered to be "cured".
  • RESULTS: Histological examination of the resected tumor tissues revealed malignancy in 43.3% (13/30).
  • Three patients had invasive malignant tumors and underwent surgery.
  • Following complete endoscopic resection, recurrences were observed in 2 patients with benign tumors, which were resected by additional endoscopic resection.
  • All patients including the two with non-invasive malignant tumors remain free from recurrence during a mean follow-up period of 45.2 months (range, 3-104 months).
  • CONCLUSIONS: EPMR of benign or non-invasive large malignant tumors is a safe and effective procedure.
  • Complete excision of large, sessile and non-invasive tumors is possible, although complete removal by EPMR cannot be verified histologically.
  • [MeSH-major] Adenoma / surgery. Carcinoma / surgery. Colorectal Neoplasms / surgery. Endoscopy, Digestive System / methods. Intestinal Mucosa / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colonoscopy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816450.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


2. Carballo M, Maish MS, Jaroszewski DE, Holmes CE: Video-assisted thoracic surgery (VATS) as a safe alternative for the resection of pulmonary metastases: a retrospective cohort study. J Cardiothorac Surg; 2009;4:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: VATS has become a preferred method for benign surgical conditions, yet still remains controversial for malignancies.
  • Primary cancers were mainly: 81 sarcoma (47%), 26 colorectal adenocarcinoma (15%) and 22 renal cell carcinoma (13%).
  • Based on our experience, it is permissible to use VATS resection in these circumstances: small tumor, fewer nodules, single lesion, age < or = 53, unilateral, tumor size amenable to wedge resection, and non-recurrent disease.
  • [MeSH-major] Adenocarcinoma / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods. Sarcoma / surgery. Thoracic Surgery, Video-Assisted / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 1995 May;109(5):997-1001; discussion 1001-2 [7739262.001]
  • [Cites] Ann Thorac Surg. 1996 Jul;62(1):213-6; discussion 216-7 [8678645.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Jan;113(1):37-49 [9011700.001]
  • [Cites] Ann Thorac Surg. 1994 Sep;58(3):712-7; discussion 717-8 [7944693.001]
  • [Cites] J Clin Epidemiol. 1989;42(6):503-11 [2661729.001]
  • [Cites] Br Med J (Clin Res Ed). 1983 May 7;286(6376):1489-93 [6405856.001]
  • [Cites] Ann Thorac Surg. 2004 Jul;78(1):238-44 [15223436.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Sep;126(3):732-9 [14502146.001]
  • [Cites] Eur J Cardiothorac Surg. 2003 Mar;23(3):397-402 [12614813.001]
  • [Cites] Stat Med. 2003 Jan 30;22(2):169-86 [12520555.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Nov;124(5):1007-13 [12407386.001]
  • [Cites] Surg Endosc. 2001 Aug;15(8):849-53 [11443456.001]
  • [Cites] Ann Thorac Surg. 2001 Jun;71(6):1885-7 [11426763.001]
  • [Cites] Chest. 2001 Apr;119(4):1069-72 [11296171.001]
  • [Cites] Lancet. 2001 Feb 10;357(9254):455-62 [11273081.001]
  • [Cites] J Am Coll Surg. 2000 Aug;191(2):184-90; discussion 190-1 [10945362.001]
  • [Cites] World J Surg. 2000 Jan;24(1):27-30; discussion 30-1 [10594199.001]
  • [Cites] Ann Thorac Surg. 1998 Apr;65(4):909-12 [9564899.001]
  • [Cites] Interact Cardiovasc Thorac Surg. 2008 Apr;7(2):212-6; discussion 216-7 [18083773.001]
  • [Cites] Ann Thorac Surg. 2007 Jul;84(1):203-10 [17588413.001]
  • [Cites] Semin Oncol. 2007 Jun;34(3):186-96 [17560980.001]
  • [Cites] Ann Thorac Surg. 2007 Jun;83(6):1965-70 [17532379.001]
  • [Cites] Ann Surg Oncol. 2007 May;14(5):1532-9 [17294075.001]
  • [Cites] Can J Neurol Sci. 2007 Mar;34 Suppl 1:S37-41 [17469680.001]
  • [Cites] J Hepatol. 2007 May;46(5):947-54 [17412447.001]
  • [Cites] ANZ J Surg. 2006 Jul;76(7):649-51 [16813634.001]
  • [Cites] Ann Thorac Surg. 1998 Dec;66(6):1903-8 [9930466.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 1998 Jun;46(6):519-22 [9720370.001]
  • (PMID = 19239710.001).
  • [ISSN] 1749-8090
  • [Journal-full-title] Journal of cardiothoracic surgery
  • [ISO-abbreviation] J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2654561
  •  go-up   go-down


3. Jeong WK, Park JW, Choi HS, Chang HJ, Jeong SY: Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center. Surg Endosc; 2009 Nov;23(11):2575-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center.
  • BACKGROUND: Transanal endoscopic microsurgery (TEM) is a minimally invasive alternative to transanal excision, enabling complete local excision of selected benign or malignant rectal tumors.
  • This study aimed to determine the surgical and oncologic results for rectal tumors excised by TEM.
  • METHODS: From November 2001 to October 2007, 45 patients underwent TEM for excision of adenoma (13 patients), carcinoid tumor (6 patients), and carcinoma (26 patients).
  • RESULTS: The median tumor distance from the anal verge was 7 cm (range, 3-15 cm), and the median tumor size was 17 mm (range, 2-60 mm).
  • No recurrence occurred for six patients with carcinoid tumors.
  • Histologic examination of the carcinomas showed pathologic tumor (pT) stage 0 (ypT0) in 2 patients, pT1 in 17 patients (including ypT1 in 1 patient), pT2 in 6 patients, and pT3 in 1 patient.
  • CONCLUSIONS: The TEM procedure is a safe and appropriate surgical treatment option for benign rectal tumors.
  • [MeSH-major] Anal Canal / surgery. Microsurgery / methods. Neoplasm Recurrence, Local / pathology. Proctoscopy / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / mortality. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Cancer Care Facilities. Carcinoid Tumor / mortality. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Korea. Male. Middle Aged. Minimally Invasive Surgical Procedures / adverse effects. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Patient Selection. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Reoperation. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2001 Sep;234(3):352-8; discussion 358-9 [11524588.001]
  • [Cites] Br J Surg. 1996 Feb;83(2):207-10 [8689164.001]
  • [Cites] Chirurg. 1984 Oct;55(10):677-80 [6510078.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1167-72 [15154642.001]
  • [Cites] Dis Colon Rectum. 1991 Oct;34(10):880-5 [1914721.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1003-8 [2754446.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] Surg Endosc. 2007 Jan;21(1):97-102 [17111281.001]
  • [Cites] Surg Endosc. 2003 Aug;17(8):1283-7 [12739119.001]
  • [Cites] Am J Surg. 2007 Nov;194(5):694-8 [17936438.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):547-56 [16514476.001]
  • [Cites] Dis Colon Rectum. 2008 Jul;51(7):1026-30; discussion 1030-1 [18481147.001]
  • [Cites] Br J Surg. 2005 Dec;92(12):1546-52 [16252312.001]
  • [Cites] Dis Colon Rectum. 1996 Aug;39(8):886-92 [8756844.001]
  • [Cites] Am J Clin Oncol. 1994 Oct;17(5):411-6 [8092113.001]
  • [Cites] Colorectal Dis. 2004 Sep;6(5):350-5 [15335369.001]
  • [Cites] World J Surg. 1992 May-Jun;16(3):437-46 [1317077.001]
  • [Cites] Surg Endosc. 2002 Jun;16(6):989-95 [12163970.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1106-11 [14597451.001]
  • [Cites] Surg Endosc. 2007 Jun;21(6):970-4 [17285371.001]
  • [Cites] Br J Surg. 2007 May;94(5):627-33 [17335125.001]
  • [Cites] Dis Colon Rectum. 1996 Sep;39(9):969-76 [8797643.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4 [10950004.001]
  • [Cites] Arch Surg. 1998 Jun;133(6):595-8; discussion 598-9 [9637456.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):581-5 [16919110.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):270-84 [15711865.001]
  • (PMID = 19347399.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


Advertisement
4. Petko Z, Ghiassi M, Shuber A, Gorham J, Smalley W, Washington MK, Schultenover S, Gautam S, Markowitz SD, Grady WM: Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res; 2005 Feb 1;11(3):1203-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps.
  • Most colon cancers arise from benign neoplasms and evolve into adenocarcinomas through a stepwise histologic progression sequence that starts from adenomas or hyperplastic polyps/serrated adenomas.
  • [MeSH-major] Biomarkers, Tumor / genetics. Colonic Polyps / genetics. Colorectal Neoplasms / genetics. DNA Methylation. DNA, Neoplasm / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adenoma / genetics. Adenoma / pathology. Carrier Proteins. Cell Line, Tumor. CpG Islands / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Feces / chemistry. Humans. Hyperplasia. Neoplasm Proteins / genetics. Nuclear Proteins. O(6)-Methylguanine-DNA Methyltransferase / genetics

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709190.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 95103; United States / NCI NIH HHS / CA / U01 CA 094986
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


5. Brozovich M, Read TE, Salgado J, Akbari RP, McCormick JT, Caushaj PF: Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution. Surg Endosc; 2008 Feb;22(2):506-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution.
  • PURPOSE: Endoscopically unresectable apparently benign colorectal polyps are considered by some surgeons as ideal for their early laparoscopic colectomy experience.
  • (1) a substantial fraction of patients undergoing laparoscopic colectomy for apparently benign colorectal neoplasia will have adenocarcinoma on final pathology; and (2) in our practice, we perform an adequate laparoscopic oncological resection for apparently benign polyps as evidenced by margin status and nodal retrieval.
  • METHODS: Data from a consecutive series of patients undergoing laparoscopic colectomy (on an intention-to-treat basis) for endoscopically unresectable neoplasms with benign preoperative histology were retrieved from a prospective database and supplemented by chart review.
  • The median nodal harvest was 12 and all resection margins were free of neoplasm.
  • Mean diameter of benign tumors was 3.2 cm (range 0.5-10.0cm) versus 3.9cm (range 1.5-7.5cm) for adenocarcinomas (p = 0.189, t - test).
  • CONCLUSION: A substantial fraction of endoscopically unresectable colorectal neoplasms with benign histology on initial biopsy will harbor invasive adenocarcinoma, some of advanced stage.
  • This finding supports the practice of performing oncological resection for all patients with endoscopically unresectable neoplasms of the colorectum.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Polyps / surgery. Colorectal Neoplasms / surgery. Laparoscopy
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Am J Surg. 1999 May;177(5):384-7 [10365875.001]
  • [Cites] Ann Surg. 1979 Dec;190(6):679-83 [518167.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1341-4 [9788858.001]
  • [Cites] AORN J. 1992 Dec;56(6):1068-73 [1463326.001]
  • [Cites] Dis Colon Rectum. 2006 Jun;49(6):879-82 [16598402.001]
  • [Cites] Surg Endosc. 2005 Sep;19(9):1252-5 [16132333.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):400-3 [17180271.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):505-8 [10215825.001]
  • (PMID = 17704872.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Ummanni R, Junker H, Zimmermann U, Venz S, Teller S, Giebel J, Scharf C, Woenckhaus C, Dombrowski F, Walther R: Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer. Cancer Lett; 2008 Aug 8;266(2):171-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prostate cancer (PCA) is the most common type of cancer found in men of western countries and is the leading cancer death next to lung cancer and colorectal cancer.
  • Prostate-specific antigen (PSA) test is an established diagnostic tool for PCA detection, but confirmation of diagnosis by histopathological evaluation of prostate needle biopsies is performed.
  • To define protein expression pattern of prostate biopsies, in the present study we investigated biopsy samples from benign prostate hyperplasia (BPH, n=11) and prostate cancer (PCA, n=12) patients by two-dimensional gel electrophoresis (2-DE) and mass spectrometry to identify potential biomarkers which might distinguish the two clinical situations.
  • The important proteins identified included prostatic acid phosphatase precursor, a significant overexpressed protein in PCA, prohibitin, NDRG1 tumor suppressor proteins, heat shock proteins, cytoskeletal proteins, enzymes like DDAH1 and ALDH2.
  • Furthermore, immunohistochemistry revealed no staining in BPH (n=13), moderate staining in prostate intra-epithelial neoplasia (PIN, n=5) but strong staining in PCA (n=18).
  • Some of the interesting proteins identified in this approach may serve to develop new targets for PCA diagnosis and treatment.
  • [MeSH-major] Biomarkers, Tumor / analysis. Prostate / pathology. Prostatic Hyperplasia / pathology. Prostatic Neoplasms / pathology. Repressor Proteins / analysis


7. Somorácz A, Tátrai P, Horváth G, Kiss A, Kupcsulik P, Kovalszky I, Schaff Z: Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas. Hum Pathol; 2010 Sep;41(9):1310-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, we proved the utility of agrin immumohistochemistry in discriminating between HCCs and benign parenchymal lesions.
  • Here, we have examined the expression of agrin in metastatic liver carcinomas in comparison with primary liver tumors.
  • Immunohistochemistry for agrin was performed on 25 HCC, 16 intrahepatic CCC, 20 colorectal cancer metastasis (CRCm), and 18 pancreatic ductal carcinoma metastasis (PDCm) samples and evaluated with both quantitative and qualitative methods.
  • Regardless of tumor grade, agrin immunostaining was strong in the microvessels of HCCs.
  • As opposed to HCC, agrin immunostaining was faint or nearly absent from the CD34-positive microvessels of CCC, CRCm, and PDCm; rather, it was detected in the basement membranes surrounding tumor cell pseudoglandules.
  • [MeSH-major] Adenoma, Liver Cell / pathology. Agrin / metabolism. Carcinoma, Hepatocellular / pathology. Colorectal Neoplasms / secondary. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / metabolism. Bile Duct Neoplasms / genetics. Bile Duct Neoplasms / metabolism. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / metabolism. Bile Ducts, Intrahepatic / pathology. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / secondary. Cholangiocarcinoma / genetics. Cholangiocarcinoma / metabolism. Cholangiocarcinoma / pathology. DNA, Neoplasm / analysis. Diagnosis, Differential. Endothelium, Vascular / metabolism. Endothelium, Vascular / pathology. Female. Gene Expression Regulation, Neoplastic. Hepatectomy. Humans. Male. Microvessels / metabolism. Microvessels / pathology. Middle Aged. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. RNA, Messenger / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20471664.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Agrin; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RNA, Messenger
  •  go-up   go-down


8. Manfredi M: Hereditary hamartomatous polyposis syndromes: understanding the disease risks as children reach adulthood. Gastroenterol Hepatol (N Y); 2010 Mar;6(3):185-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hamartomatous polyposis syndromes are a rare group of hereditary autosomal dominant disorders that comprise less than 1% of all hereditary colorectal cancers.
  • Hamartomatous polyps, in and of themselves, are benign entities; however, these hamartomatous polyposis syndromes have a malignant potential for the development of colorectal cancer as well as extracolonic cancers.
  • This article provides a critical review of the clinical presentation, pathology, genetics, and screening and surveillance guidelines of juvenile polyposis syndrome, PTEN hamartoma tumor syndrome, and Peutz-Jeghers syndrome.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 1995 Jul;118(1):115-7 [7604372.001]
  • [Cites] J Med Genet. 1995 Feb;32(2):117-9 [7760320.001]
  • [Cites] J Pediatr Surg. 1994 Dec;29(12):1584-7 [7877037.001]
  • [Cites] Br J Surg. 1995 Jan;82(1):14-7 [7881943.001]
  • [Cites] J Clin Gastroenterol. 1994 Jan;18(1):42-7 [8113585.001]
  • [Cites] Cytogenet Cell Genet. 1993;64(3-4):204-7 [8404038.001]
  • [Cites] Genes Dev. 1995 Dec 15;9(24):3027-37 [8543149.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Nat Genet. 1996 May;13(1):114-6 [8673088.001]
  • [Cites] Cell. 1996 Jun 28;85(7):947-50 [8674122.001]
  • [Cites] Nat Genet. 1997 Jan;15(1):87-90 [8988175.001]
  • [Cites] Nat Genet. 1997 May;16(1):64-7 [9140396.001]
  • [Cites] Cytokine Growth Factor Rev. 1997 Mar;8(1):11-20 [9174660.001]
  • [Cites] Nat Genet. 1997 Aug;16(4):333-4 [9241266.001]
  • [Cites] Hum Mol Genet. 1997 Aug;6(8):1383-7 [9259288.001]
  • [Cites] Am J Med Genet. 1997 Sep 5;71(4):489-93 [9286463.001]
  • [Cites] Nature. 1997 Dec 4;390(6659):465-71 [9393997.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2004 Aug;39(2):219-20 [15269641.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6445-70 [15322516.001]
  • [Cites] J Clin Pathol. 2005 Jan;58(1):15-9 [15623475.001]
  • [Cites] Dis Colon Rectum. 2005 Jan;48(1):49-55; discussion 55-6 [15690657.001]
  • [Cites] Hum Mol Genet. 2005 May 15;14(10):1283-92 [15800014.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Nov;20(11):1634-40 [16246179.001]
  • [Cites] JAMA. 2005 Nov 16;294(19):2465-73 [16287957.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):184-96 [16412571.001]
  • [Cites] Gastroenterol Nurs. 2006 Jan-Feb;29(1):16-22; quiz 23-4 [16552295.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Apr;4(4):408-15 [16616343.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3209-15 [16707622.001]
  • [Cites] Am J Hum Genet. 2006 Jul;79(1):23-30 [16773562.001]
  • [Cites] Nat Rev Cancer. 2007 Jan;7(1):35-45 [17167516.001]
  • [Cites] Clin Genet. 2007 Jan;71(1):91-2 [17204053.001]
  • [Cites] Curr Mol Med. 2007 Feb;7(1):29-46 [17311531.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2007 Sep;4(9):492-502 [17768394.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):927-46, viii [17996798.001]
  • [Cites] Gastroenterology. 1978 Jun;74(6):1325-30 [348556.001]
  • [Cites] Gastroenterology. 1979 Jul;77(1):148-51 [447014.001]
  • [Cites] Johns Hopkins Med J. 1975 Feb;136(2):71-82 [1117595.001]
  • [Cites] Ann Intern Med. 1975 Nov;83(5):639-46 [1200496.001]
  • [Cites] Am J Med Genet. 1992 Oct 1;44(3):307-14 [1336932.001]
  • [Cites] Cancer. 1992 Aug 15;70(4):869-76 [1643619.001]
  • [Cites] Arch Dis Child. 1991 Aug;66(8):971-5 [1656892.001]
  • [Cites] Bull World Health Organ. 1990;68(5):655-65 [2289301.001]
  • [Cites] Endoscopy. 1988 Jan;20(1):33-5 [2830104.001]
  • [Cites] Histopathology. 1988 Dec;13(6):619-30 [2853131.001]
  • [Cites] Turk J Pediatr. 1988 Apr-Jun;30(2):99-103 [3242187.001]
  • [Cites] N Engl J Med. 1987 Jun 11;316(24):1511-4 [3587280.001]
  • [Cites] Am J Surg Pathol. 1987 Oct;11(10):743-9 [3661821.001]
  • [Cites] Clin Genet. 1986 Mar;29(3):222-33 [3698331.001]
  • [Cites] Am J Ophthalmol. 1986 Jul 15;102(1):126-7 [3728618.001]
  • [Cites] Gastroenterology. 1969 Oct;57(4):431-8 [4378049.001]
  • [Cites] Surgery. 1974 Jan;75(1):107-14 [4543470.001]
  • [Cites] J Ky Med Assoc. 1972 Jul;70(7):540-4 [5038441.001]
  • [Cites] Cancer. 1970 May;25(5):1107-21 [5429475.001]
  • [Cites] Gastroenterology. 1970 May;58(5):699-708 [5444174.001]
  • [Cites] J Med Genet. 1966 Mar;3(1):5-16 [5911834.001]
  • [Cites] Am J Surg Pathol. 1984 Oct;8(10):763-70 [6496844.001]
  • [Cites] Cancer. 1980 Jul 1;46(1):223-8 [6770991.001]
  • [Cites] J Pediatr Surg. 1983 Feb;18(1):1-6 [6834218.001]
  • [Cites] J R Soc Med. 1983 Aug;76(8):701-3 [6887190.001]
  • [Cites] Dis Colon Rectum. 1981 Apr;24(3):205-10 [6971747.001]
  • [Cites] Clin Genet. 1980 Dec;18(6):413-6 [7449178.001]
  • [Cites] Ann Surg Oncol. 1995 Sep;2(5):386-91 [7496832.001]
  • [Cites] J Am Coll Surg. 1995 Nov;181(5):407-13 [7582207.001]
  • [Cites] Am J Hum Genet. 1997 Dec;61(6):1254-60 [9399897.001]
  • [Cites] Am J Hum Genet. 1997 Dec;61(6):1327-34 [9399902.001]
  • [Cites] Genes Dev. 1998 Jan 1;12(1):107-19 [9420335.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):38-43 [9425897.001]
  • [Cites] Nature. 1998 Jan 8;391(6663):184-7 [9428765.001]
  • [Cites] Hum Mol Genet. 1998 Mar;7(3):507-15 [9467011.001]
  • [Cites] Cell. 1998 Mar 6;92(5):645-56 [9506519.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3667-72 [9520423.001]
  • [Cites] Am J Hum Genet. 1998 May;62(5):1129-36 [9545410.001]
  • [Cites] Am J Hum Genet. 1998 May;62(5):1020-2 [9545417.001]
  • [Cites] Clin Pediatr (Phila). 1998 Apr;37(4):253-7 [9564575.001]
  • [Cites] Science. 1998 May 15;280(5366):1086-8 [9582123.001]
  • [Cites] Science. 1998 May 15;280(5366):1036-7 [9616081.001]
  • [Cites] J Med Genet. 1998 Jun;35(6):476-81 [9643289.001]
  • [Cites] Curr Biol. 1998 Oct 22;8(21):1169-78 [9799734.001]
  • [Cites] J Med Genet. 1998 Nov;35(11):886-9 [9832032.001]
  • [Cites] Ann Surg Oncol. 1998 Dec;5(8):751-6 [9869523.001]
  • [Cites] Am J Med Sci. 1999 Jan;317(1):59-62 [9892274.001]
  • [Cites] J Med Genet. 1999 May;36(5):360-4 [10353779.001]
  • [Cites] Hum Mol Genet. 1999 Aug;8(8):1461-72 [10400993.001]
  • [Cites] Surgery. 1999 Aug;126(2):162-70 [10455879.001]
  • [Cites] J Clin Invest. 1999 Nov;104(10):1343-51 [10562296.001]
  • [Cites] Intern Med. 2000 Jul;39(7):559-63 [10888212.001]
  • [Cites] J Med Genet. 2000 Nov;37(11):828-30 [11073535.001]
  • [Cites] Gastroenterology. 2000 Dec;119(6):1447-53 [11113065.001]
  • [Cites] J Med Genet. 2001 Mar;38(3):159-64 [11238682.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):319-27 [11352305.001]
  • [Cites] Nat Genet. 2001 Jun;28(2):105-7 [11381248.001]
  • [Cites] Nat Genet. 2001 Jun;28(2):184-7 [11381269.001]
  • [Cites] J Cell Physiol. 2001 Jul;188(1):1-7 [11382917.001]
  • [Cites] Am J Hum Genet. 2001 Oct;69(4):704-11 [11536076.001]
  • [Cites] Am J Hum Genet. 2002 Apr;70(4):829-44 [11875759.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2261-6 [11956081.001]
  • [Cites] Arch Pathol Lab Med. 1996 Nov;120(11):1032-8 [12049105.001]
  • [Cites] Gut. 2002 Oct;51 Suppl 5:V21-7 [12221036.001]
  • [Cites] Biochem Cell Biol. 2002;80(5):605-22 [12440701.001]
  • [Cites] Clin Genet. 2003 Feb;63(2):126-30 [12630959.001]
  • [Cites] Am J Gastroenterol. 2003 Jun;98(6):1429-34 [12818292.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):308-13 [12865922.001]
  • [Cites] N Engl J Med. 1957 Jun 20;256(25):1186-90; concl [13452019.001]
  • [Cites] Cancer. 1957 Nov-Dec;10(6):1210-20 [13489673.001]
  • [Cites] Surg Gynecol Obstet. 1962 Jul;115:1-11 [13865437.001]
  • [Cites] Proc R Soc Med. 1964 Oct;57:896-7 [14214792.001]
  • [Cites] Am J Dig Dis. 1960 Jun;5:576-7 [14412980.001]
  • [Cites] Fam Cancer. 2001;1(2):121-5 [14574008.001]
  • [Cites] J Med Genet. 2004 Jul;41(7):484-91 [15235019.001]
  • [Cites] Am J Med Genet C Semin Med Genet. 2004 Aug 15;129C(1):44-55 [15264272.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14(7):1931-7 [18381930.001]
  • [Cites] Surg Clin North Am. 2008 Aug;88(4):779-817, vii [18672141.001]
  • (PMID = 20567567.001).
  • [ISSN] 1554-7914
  • [Journal-full-title] Gastroenterology & hepatology
  • [ISO-abbreviation] Gastroenterol Hepatol (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2886463
  • [Keywords] NOTNLM ; Hamartomatous polyposis syndromes / PTEN hamartoma tumor syndrome / Peutz-Jeghers syndrome / juvenile polyposis syndrome
  •  go-up   go-down


9. Koh DM, Brown G, Meer Z, Norman AR, Husband JE: Diagnostic accuracy of rim and segmental MRI enhancement of colorectal hepatic metastasis after administration of mangafodipir trisodium. AJR Am J Roentgenol; 2007 Feb;188(2):W154-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic accuracy of rim and segmental MRI enhancement of colorectal hepatic metastasis after administration of mangafodipir trisodium.
  • OBJECTIVE: The purpose of this study was to determine the diagnostic accuracy of rim and segmental MRI enhancement of hepatic metastasis of colorectal cancer after administration of mangafodipir trisodium (MnDPDP).
  • SUBJECTS AND METHODS: Sixty-one patients with a potentially resectable hepatic metastasis of colorectal cancer consecutively underwent breath-hold T1-weighted MRI in the axial and coronal planes 30 minutes and 24 hours after administration of MnDPDP.
  • RESULTS: Two hundred thirty lesions were identified at MRI: 210 lesions were metastatic, and 20 were benign.
  • CONCLUSION: Rim and segmental enhancement at MRI 24 hours after MnDPDP administration enabled accurate characterization of hepatic colorectal metastasis.
  • These features may aid in preoperative mapping of hepatic tumor burden and disease distribution in patients with colorectal cancer.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Edetic Acid / analogs & derivatives. Image Enhancement / methods. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Magnetic Resonance Imaging / methods. Pyridoxal Phosphate / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. Disodium EDTA .
  • Hazardous Substances Data Bank. ETHYLENEDIAMINE TETRAACETIC ACID .
  • Hazardous Substances Data Bank. DISODIUM CALCIUM EDTA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17242222.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 5V5IOJ8338 / Pyridoxal Phosphate; 9G34HU7RV0 / Edetic Acid; P28BIW0UTB / N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid
  •  go-up   go-down


10. Maruthachalam K, Lash GE, Shenton BK, Horgan AF: Tumour cell dissemination following endoscopic stent insertion. Br J Surg; 2007 Sep;94(9):1151-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour cell dissemination following endoscopic stent insertion.
  • BACKGROUND: This study examined whether colonoscopy or endoscopic stent insertion increases levels of carcinoembryonic antigen (CEA) and/or cytokeratin (CK) 20 mRNA expression in the peripheral circulation of patients with colorectal cancer.
  • Twenty patients undergoing colonoscopy for benign conditions served as controls.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Colorectal Neoplasms / surgery. Keratin-20 / blood. Neoplastic Cells, Circulating / metabolism. Stents / adverse effects

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • [CommentIn] Br J Surg. 2008 Jan;95(1):127-8; author reply 128 [18161907.001]
  • (PMID = 17541987.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-20; 0 / RNA, Messenger
  •  go-up   go-down


11. Pasquini P, Baiocchini A, Falasca L, Annibali D, Gimbo G, Pace F, Del Nonno F: Mucosal Schwann cell "Hamartoma": a new entity? World J Gastroenterol; 2009 May 14;15(18):2287-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Schwannoma is a well-described, benign nerve sheath tumor of the soft tissue, but is rare in the gastrointestinal tract.
  • To avoid confusion of these solitary colorectal polyps containing pure spindled Schwann cell proliferation in the lamina propria with neural lesions that have significant association with inherited syndromes, it is better to use the designation "mucosal Schwann hamartoma".
  • [MeSH-major] Hamartoma / pathology. Neurilemmoma / pathology. Schwann Cells / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):431-6 [10199472.001]
  • [Cites] Adv Anat Pathol. 1999 Jan;6(1):19-40 [10197236.001]
  • [Cites] AJR Am J Roentgenol. 2005 Mar;184(3):797-802 [15728600.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10):1310-5 [16160473.001]
  • [Cites] Histopathology. 2006 Apr;48(5):536-45 [16623779.001]
  • [Cites] Am J Surg Pathol. 2009 May;33(5):781-7 [19065103.001]
  • [Cites] Surg Oncol. 2000 Nov;9(3):111-8 [11356339.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):846-55 [11420455.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):578-82 [11431711.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Pathol Res Pract. 2002;198(9):605-13 [12440783.001]
  • [Cites] Scand J Gastroenterol. 2003 Dec;38(12):1275-8 [14750649.001]
  • [Cites] Hum Pathol. 1988 Mar;19(3):257-64 [3126126.001]
  • [Cites] J Clin Gastroenterol. 1994 Jan;18(1):13-8 [8113577.001]
  • [Cites] Histopathology. 1995 Oct;27(4):355-60 [8847066.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):162-8 [15654796.001]
  • (PMID = 19437573.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2682248
  •  go-up   go-down


12. Fujii H, Jiang W, Matsumoto T, Miyai K, Sashara K, Ohtsuji N, Hino O: Birt-Hogg-Dubé gene mutations in human endometrial carcinomas with microsatellite instability. J Pathol; 2006 Jul;209(3):328-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Birt-Hogg-Dubé (BHD) syndrome is a rare form of autosomal dominantly inherited genodermatosis characterized by benign hamartomatous skin lesions named fibrofolliculomas, and an increased risk for developing pulmonary cyst/pneumothorax and various forms of renal cell carcinoma.
  • This mutational hot spot is also reported to be a target of mutation in microsatellite instability (MSI) sporadic colorectal cancer.
  • Of these, one showed additional mutation in exon 4, possibly satisfying the two-hit hypothesis of tumour suppressor genes.
  • When multiple foci were microdissected and individually screened for mutation, BHD mutations were shown to have been acquired during tumour progression, after mutation of the BAX gene, in three of five cases.
  • [MeSH-major] Endometrial Neoplasms / genetics. Microsatellite Repeats / genetics. Mutation. Neoplastic Syndromes, Hereditary / genetics. Proteins / genetics. Proto-Oncogene Proteins / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adult. Aged. Aged, 80 and over. Base Sequence. Carrier Proteins / genetics. DNA Methylation. DNA-Binding Proteins / genetics. Disease Progression. Female. Humans. Microdissection / methods. Middle Aged. Molecular Sequence Data. Neoplasm Proteins / genetics. Nuclear Proteins / genetics. bcl-2-Associated X Protein / genetics

  • Genetic Alliance. consumer health - Birt-Hogg-Dube Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Pathological Society of Great Britain and Ireland.
  • (PMID = 16691634.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / FLCN protein, human; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Proteins; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


13. Aqueveque A C, González E P, Gutiérrez B D, Jaimovich F R, Díaz P JC, Csendes G P, Orellana P P, Lavados M H, Alliende G I, Araya L S: [Fusion of SPECT with computed tomography or magnetic resonance for the interpretation of abnormal tracer uptake]. Rev Med Chil; 2007 Jun;135(6):725-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These were classified before and after the fusion as probably malignant or probably benign.
  • Therefore the suspicion of malignancy was presumptively confirmed in 72% of foci and fusion results would have reached a 27% of incremental diagnostic value in 14 cases that changed of category (11 with differentiated thyroid carcinoma, one with colorectal cancer, one with a nasal Ewing sarcoma and one with a brain tumor).
  • [MeSH-major] Carcinoma / diagnosis. Magnetic Resonance Imaging / methods. Radiopharmaceuticals. Thyroid Neoplasms / diagnosis. Tomography, Emission-Computed, Single-Photon / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17728898.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


14. Merenda R, Portale G, Galeazzi F, Tosolini C, Sturniolo GC, Ancona E: Pancreaticoduodenectomy for dysplastic duodenal adenoma in a patient with familial adenomatous polyposis. Tumori; 2008 Nov-Dec;94(6):882-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal polyposis is the main feature of familial adenomatous polyposis (FAP), but benign and malignant lesions have also been described in the stomach, duodenum, small bowel, biliary tract and pancreas.
  • This report described the rare case of a patient presenting with duodenal adenomas with dysplastic changes and tumor infiltration as the first sign of FAP, who was treated by pancreaticoduodenectomy followed by proctocolectomy for subsequent dysplastic changes in colonic polyps.
  • [MeSH-major] Adenoma / surgery. Adenomatous Polyposis Coli / surgery. Colonic Polyps / pathology. Duodenal Neoplasms / surgery. Pancreaticoduodenectomy


15. Sheng SL, Huang G, Yu B, Qin WX: Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem; 2009 Sep;55(9):1656-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By use of this method, we investigated the serum concentrations of DKK1 in 592 patients with malignancies, 72 patients with benign lung disease, and 120 healthy controls.
  • RESULTS: Serum DKK1 concentrations were significantly higher in patients with lung cancer than in patients with other malignant tumors or benign lung diseases and healthy controls.
  • Serum concentrations of DKK1 were decreased significantly in groups of patients with gastric cancer, colorectal cancer, ovarian cancer, and cervical adenocarcinoma compared with healthy controls.
  • DKK1 concentrations increased with stage, tumor class, and presence of lymph node and distant metastases, regardless of histology and patient age and sex.
  • Increasing concentrations of DKK1were significantly associated with tumor progression and decreased survival in patients with lung cancer. .
  • [MeSH-major] Biomarkers, Tumor / blood. Fluoroimmunoassay / methods. Intercellular Signaling Peptides and Proteins / blood. Lung Neoplasms / blood
  • [MeSH-minor] Aged. Calibration. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19628661.001).
  • [ISSN] 1530-8561
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DKK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins
  •  go-up   go-down


16. Hao RT, Zhang XH, Pan YF, Liu HG, Xiang YQ, Wan L, Wu XL: Prognostic and metastatic value of phosphatase of regenerating liver-3 in invasive breast cancer. J Cancer Res Clin Oncol; 2010 Sep;136(9):1349-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: We found that 70.7% patients expressed a high level of PRL-3 protein in their tumors, and its over expression was positive correlated with lymph node metastasis (LNM) (P = 0.011).
  • Moreover, The PRL-3 mRNA expression was significantly higher in malignant compared to benign breast tissue, while increased expression of PRL-3 mRNA was significantly associated with LNM (P = 0.002).
  • Increasing the risk of tumor metastasis (OR = 3.889).
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / enzymology. Neoplasm Proteins / metabolism. Protein Tyrosine Phosphatases / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Lymphatic Metastasis / pathology. Middle Aged. Neoplasm Invasiveness / diagnosis. Prognosis. RNA, Messenger / biosynthesis. Recurrence. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Mol Med. 2008 Aug;22(2):187-92 [18636172.001]
  • [Cites] Biochem Biophys Res Commun. 2001 May 25;283(5):1061-8 [11355880.001]
  • [Cites] Ann Oncol. 2006 Oct;17(10):1517-22 [16873432.001]
  • [Cites] Pathobiology. 2004;71(4):176-84 [15263806.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):2922-6 [17409395.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Sep;130(9):521-6 [15133662.001]
  • [Cites] Mol Med. 2007 Mar-Apr;13(3-4):151-9 [17592549.001]
  • [Cites] Arch Pathol Lab Med. 2008 Aug;132(8):1307-12 [18684031.001]
  • [Cites] Am J Pathol. 2004 Jun;164(6):2039-54 [15161639.001]
  • [Cites] Virchows Arch. 2007 Mar;450(3):303-10 [17235563.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21444-52 [10747914.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 15;348(1):229-37 [16875667.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2195-204 [15788667.001]
  • [Cites] Int J Colorectal Dis. 2007 Oct;22(10):1179-84 [17440740.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5607-15 [14654542.001]
  • [Cites] Surg Today. 2007;37(8):646-51 [17643206.001]
  • [Cites] Mol Cell Biol. 1994 Jun;14(6):3752-62 [8196618.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7857-66 [15520192.001]
  • [Cites] Int J Cancer. 2008 Sep 15;123(6):1439-47 [18561324.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 31;342(1):179-83 [16472776.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3153-61 [16540666.001]
  • [Cites] Cancer Lett. 1996 Dec 20;110(1-2):49-55 [9018080.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7318-28 [15534108.001]
  • [Cites] Science. 2001 Nov 9;294(5545):1343-6 [11598267.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2716-22 [12782572.001]
  • [Cites] Science. 2001 Oct 12;294(5541):281-2 [11598274.001]
  • [Cites] Mol Cancer Ther. 2006 Feb;5(2):219-29 [16505094.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6835-9 [16203771.001]
  • [Cites] J Biol Chem. 2004 Mar 19;279(12):11882-9 [14704153.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):347-54 [16832410.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9625-35 [17018620.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 17;244(2):421-7 [9514946.001]
  • [Cites] Cancer Biol Ther. 2004 Oct;3(10):945-51 [15326366.001]
  • [Cites] Mol Cell. 2008 May 9;30(3):303-14 [18471976.001]
  • (PMID = 20140626.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


17. Pontes ER, Matos LC, da Silva EA, Xavier LS, Diaz BL, Small IA, Reis EM, Verjovski-Almeida S, Barcinski MA, Gimba ER: Auto-antibodies in prostate cancer: humoral immune response to antigenic determinants coded by the differentially expressed transcripts FLJ23438 and VAMP3. Prostate; 2006 Oct 1;66(14):1463-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Here we evaluate auto-antibody response against two potential antigenic determinants of genes highly expressed in low Gleason Score prostate cancer (PC) tumor samples, namely FLJ23438 and VAMP3.
  • The auto-antibody response against FLJ23438 and VAMP3 recombinant proteins was tested by immunoblot assays using PC, benign prostate hyperplasia (BPH), healthy donors (HD), and other human cancers plasma samples.
  • [MeSH-major] Adenocarcinoma / immunology. Autoantibodies / blood. Biomarkers, Tumor / immunology. Prostatic Neoplasms / immunology. Vesicle-Associated Membrane Protein 3 / immunology
  • [MeSH-minor] Aged. Antigens / genetics. Antigens / immunology. Breast Neoplasms. Carcinoma, Squamous Cell. Cell Line, Tumor. Colorectal Neoplasms. Esophageal Neoplasms. Gene Expression Regulation, Neoplastic. Humans. Lung Neoplasms. Male. Middle Aged. Open Reading Frames / genetics. Prostatic Hyperplasia / epidemiology. Prostatic Hyperplasia / immunology. Prostatic Hyperplasia / physiopathology. RNA, Messenger / genetics. RNA, Small Nuclear / genetics. RNA, Small Nuclear / immunology. Recombinant Proteins / genetics. Recombinant Proteins / immunology. Seroepidemiologic Studies

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16897729.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Small Nuclear; 0 / Recombinant Proteins; 0 / U2 small nuclear RNA; 0 / VAMP3 protein, human; 0 / Vesicle-Associated Membrane Protein 3
  •  go-up   go-down


18. Amegbor K, Napo-Koura GA, Songne-Gnamkoulamba B, Redah D, Tekou A: Epidemiological and pathological aspects of gastrointestinal tumors in Togo. Gastroenterol Clin Biol; 2008 Apr;32(4):430-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiological and pathological aspects of gastrointestinal tumors in Togo.
  • PURPOSE: The incidence of gastrointestinal tumors is difficult to estimate in Togo, so the purpose of this report was to describe the tumors diagnosed by the national pathology laboratory.
  • METHODS: This was a retrospective descriptive study of 742 gastrointestinal tumors diagnosed between 1986 and 2005 by the pathology laboratory of the Tokoin university hospital in Lomé, Togo.
  • RESULTS: There was an annual incidence of 37 gastrointestinal tumors, including 27 cancers, with twice as many tumors diagnosed in men as in women.
  • The average age of patients diagnosed with a benign tumor was 44 years compared with 52 years for those with a malignant tumor.
  • Stomach tumors predominated (n=306; 41.2%).
  • Papilloma was the most frequent benign tumor type (n=100; 47.8%), while malignant tumors were mostly gastric adenocarcinoma (n=224; 42% of all cancers), esophageal squamous cell carcinoma (n=100; 19%) and colorectal adenocarcinoma (n=89; 17%).
  • CONCLUSION: Gastrointestinal tumors are frequently seen in Togo, and an epidemiological monitoring program is needed.
  • [MeSH-major] Gastrointestinal Neoplasms / epidemiology. Gastrointestinal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18359594.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


19. Brankovic B, Radisavljevic M, Radojkovic M, Stanojevic G, Stojanovic M, Nagorni A, Radojkovic D, Jeremic L, Nestorovic M, Karamarkovic A: Nonfunctional retroperitoneal paraganglioma presenting as acute upper gastrointestinal hemorrhage. Hepatogastroenterology; 2010 Mar-Apr;57(98):288-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Paragangliomas are very rare tumors arising from extraadrenal chromaffin cells.
  • Clinical presentation of benign retroperitoneal nonfunctional paraganglioma is unspecific.
  • Symptoms may occur when tumor attains a remarkable size or when complications arise.
  • This article reports a case of nonfunctional retroperitoneal paraganglioma as a cause of acute upper gastrointestinal hemorrhage which represents the unusual urgent clinical manifestation of these tumors.
  • The presented case emphasizes the necessity to include extraadrenal paraganglioma in the differential diagnosis in all patients with retroperitoneal mass found even in the presence of at first appearance non-related emergency condition like acute upper gastrointestinal bleeding.
  • [MeSH-major] Gastrointestinal Hemorrhage / diagnosis. Paraganglioma / diagnosis. Retroperitoneal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583429.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


20. Pesta M, Holubec L Jr, Topolcan O, Cerna M, Rupert K, Holubec LS, Treska V, Kormunda S, Elgrova L, Finek J, Cerny R: Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples. Anticancer Res; 2005 Sep-Oct;25(5):3387-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
  • BACKGROUND: An essential step in the process of tumor invasion and metastasis involves the degradation of tissue barriers in the extracellular matrix (ECM), particularly in the basal membrane (BM).
  • Matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs), in particular MMP-2, MMP-7, TIMP-1 and TIMP-2, play an important role in the process of ECM and BM degradation in connection with tumor invasion.
  • The aim of our study was to assess the levels of MMP-2, MMP-7, TIMP-1 and TIMP-2 mRNA expression in colorectal carcinoma tissue samples and to correlate them with the stage of the disease.
  • PATIENTS AND METHODS: The study included samples of tumor tissue of 38 patients with colorectal carcinoma and samples of tissue of 11 patients with benign disease.
  • RESULTS: The levels of mRNA expression of MMP-2, MMP-7 and TIMP-1 were significantly higher in tumor tissue samples that in the control tissue (p<0.0005, p<0.0007 and p<0.0004).
  • In addition the presence of mRNA MMP-2, MMP-7, TIMP-1 and TIMP-2 in tumor tissue samples in these parameters was significantly higher than in the control tissue (p<0.003, p<0.0001, p<0.0001 and p<0.05).
  • CONCLUSION: This pilot study demonstrated that a significant difference in the level and in the presence of mRNA MMP-2, MMP-7 and TIMP-1 expressions between tumor colorectal and control colorectal tissues might be helpful for the prognosis of colorectal cancer.
  • [MeSH-major] Colorectal Neoplasms / enzymology. Matrix Metalloproteinase 2 / biosynthesis. Matrix Metalloproteinase 7 / biosynthesis. Tissue Inhibitor of Metalloproteinase-1 / biosynthesis. Tissue Inhibitor of Metalloproteinase-2 / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101153.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinase-1; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


21. Okubo H, Ozeki K, Tanaka T, Matsuo T, Mochinaga N: Primary malignant fibrous histiocytoma of the ascending colon: report of a case. Surg Today; 2005;35(4):323-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 66-year-old man presented to our hospital with epigastralgia, and abdominal ultrasonography and computed tomography showed a large soft-tissue mass in the ascending colon.
  • Barium enema and endoscopic examination showed a huge tumor in the ascending colon.
  • At laparotomy, we found a tumor in the ascending colon and performed a right hemicolectomy with en bloc lymph node dissection.
  • The resected specimen contained a tumor measuring 14.5 x 8.0 x 4.5 cm, the cut surface of which was yellowish.
  • Based on histological and immunohistological studies, the tumor was diagnosed as MFH of the ascending colon.
  • To our knowledge, only 20 cases of colorectal MFH, including our case, have been documented, which we review following this case report.
  • [MeSH-major] Colon, Ascending. Colonic Neoplasms / surgery. Histiocytoma, Benign Fibrous / surgery
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15815852.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Ohta M, Seto M, Ijichi H, Miyabayashi K, Kudo Y, Mohri D, Asaoka Y, Tada M, Tanaka Y, Ikenoue T, Kanai F, Kawabe T, Omata M: Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression. Gastroenterology; 2009 Jan;136(1):206-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression.
  • BACKGROUND & AIMS: Although colorectal cancer (CRC) progression has been associated with alterations in KRAS and RAS signaling, not all CRC cells have KRAS gene mutations.
  • The expression of the RAS protein activator like-1 (RASAL1) was examined in clinical colorectal neoplasms using immunohistochemistry.
  • The clinicopathologic (age, sex, and tumor site and grade) and molecular (KRAS gene mutation, as well as CTNNB1 and TP53 expression patterns) factors that could affect RASAL1 expression were examined.
  • RASAL1 expression was detected in 46.9% (30/64) of adenocarcinoma, 17.4% (8/46) of large adenoma, and no (0/42) small adenoma samples.
  • RASAL1 expression levels were correlated with the presence of wild-type KRAS gene in CRC tumor samples (P= .0010), distal location (P= .0066), and abnormal expression of TP53 (P= .0208).
  • Reductions in RASAL1 expression were detected more frequently in advanced lesions than in small adenomas, suggesting that RASAL1 functions in the progression of benign colonic neoplasms.
  • [MeSH-major] Colorectal Neoplasms / etiology. Tumor Suppressor Proteins / physiology. ras GTPase-Activating Proteins / physiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. DNA Methylation. Disease Progression. Female. Gene Silencing. Genes, ras. Humans. Male. Middle Aged. Signal Transduction


23. Guillem JG, Chessin DB, Jeong SY, Kim W, Fogarty JM: Contemporary applications of transanal endoscopic microsurgery: technical innovations and limitations. Clin Colorectal Cancer; 2005 Nov;5(4):268-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Transanal endoscopic microsurgery (TEM) is a minimally invasive procedure used to transanally excise select benign and malignant tumors of the rectum.
  • PATIENTS AND METHODS: Thirty-two consecutive patients scheduled for TEM were identified from our prospectively maintained colorectal service database.
  • In addition, a PubMed literature search was performed with use of the key words "transanal endoscopic microsurgery," "TEM," "rectal tumor," and "rectal cancer."
  • RESULTS: Transanal endoscopic microsurgery was performed for rectal adenocarcinoma (n = 17; 53%), adenoma (n = 12; 38%), and carcinoid tumors (n = 3; 9%).
  • Median tumor location was 9 cm from the anal verge (range, 3-15 cm).
  • Reasons for inability to complete TEM included narrow rectal lumen or contour of bony pelvis prohibiting passage of the operating proctoscope into the upper rectum and inability to maintain the proctoscope in the rectal lumen with carbon dioxide insufflation because of the distal location of the tumor.
  • Innovations used in the excision of rectal tumors via TEM included the use of the harmonic scalpel, closure of the rectal defect with an extracorporeal slip knot, and a hybrid approach incorporating TEM and traditional transanal techniques.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Carcinoid Tumor / surgery. Colonoscopy / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Female. Humans. Male. Microsurgery. Middle Aged. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16356304.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Regöly-Mérei A, Bereczky M, Arató G, Telek G, Pallai Z, Lugasi A, Antal M: [Nutritional and antioxidant status of colorectal cancer patients]. Orv Hetil; 2007 Aug 12;148(32):1505-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nutritional and antioxidant status of colorectal cancer patients].
  • INTRODUCTION: Oxidative stress is one of the risk factors of colorectal carcinogenesis.
  • In inflammatory reactions the activated leucocytes product mutagenic and mitogenic free radicals, hereby promoting tumor formation.
  • AIM: Evaluation of some parameters of antioxidant and nutritional status in patients with benign or malignant colorectal neoplasm.
  • RESULTS: In patients with malignant tumor the dietary fiber, folate and vitamin A intake was under the optimal level, and the serum prealbumin concentration was lower than in patients with benign lesion.
  • CONCLUSIONS: The insufficient folate and vitamin A intake, the high incidence of overweight and obesity, and the abnormal values of the biomarkers of antioxidant status observed in the study groups seem to support the correlation between colorectal tumor, nutritional and antioxidant status.
  • [MeSH-major] Adenoma / blood. Antioxidants / metabolism. Carcinoma / blood. Colorectal Neoplasms / blood. Free Radical Scavengers / blood. Nutritional Status

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. VITAMIN A .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17675278.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers; 0 / Free Radical Scavengers; 0 / Prealbumin; 11103-57-4 / Vitamin A; 4Y8F71G49Q / Malondialdehyde; 935E97BOY8 / Folic Acid; EC 1.11.1.9 / Glutathione Peroxidase
  •  go-up   go-down


25. Atallah S, Albert M, Larach S: Transanal minimally invasive surgery: a giant leap forward. Surg Endosc; 2010 Sep;24(9):2200-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the clinical application of this technique and present preliminary data that show TAMIS to be an effective tool for resection of both malignant and benign lesions of the rectum.
  • Patients with biopsy-proven malignant lesions were required to undergo endorectal ultrasound preoperatively to determine tumor stage.
  • The average distance from the anal verge was 9.3 cm and the mean tumor diameter confirmed by pathology measured 2.93 cm.
  • [MeSH-major] Laparoscopy / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Biopsy. Endosonography. Female. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures. Neoplasm Staging. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Colorectal Dis. 2008 Oct;23(10):1013-6 [18607608.001]
  • [Cites] World J Surg. 2009 May;33(5):1015-9 [19116734.001]
  • [Cites] Dis Colon Rectum. 2002 May;45(5):601-4 [12004207.001]
  • [Cites] Dis Colon Rectum. 2009 Jun;52(6):1107-13 [19581854.001]
  • [Cites] Colorectal Dis. 2007 Jul;9(6):553-8 [17573752.001]
  • [Cites] Colorectal Dis. 2008 Oct;10(8):823-6 [18684153.001]
  • [Cites] Surg Endosc. 2009 Jul;23(7):1419-27 [19347400.001]
  • [Cites] Surg Endosc. 2010 Feb;24(2):445-9 [19565297.001]
  • [Cites] Dis Colon Rectum. 2008 Jul;51(7):1026-30; discussion 1030-1 [18481147.001]
  • [Cites] Asian J Surg. 2006 Oct;29(4):227-32 [17098653.001]
  • [Cites] Gastrointest Endosc. 2009 Jul;70(1):193-4 [19559847.001]
  • [Cites] Leber Magen Darm. 1985 Nov;15(6):271-9 [4079630.001]
  • [Cites] J Gastrointest Surg. 2009 Sep;13(9):1733-40 [19412642.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1376-80 [14571741.001]
  • [Cites] Minerva Chir. 2009 Aug;64(4):355-64 [19648856.001]
  • [Cites] Surg Technol Int. 2009 Apr;18:19-25 [19579186.001]
  • [Cites] Urology. 2009 Oct;74(4):805-12 [19643465.001]
  • [Cites] Colorectal Dis. 2006 Nov;8(9):795-9 [17032328.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1106-11 [14597451.001]
  • [Cites] Int Semin Surg Oncol. 2006 May 04;3:13 [16674824.001]
  • [Cites] Dis Colon Rectum. 1996 Sep;39(9):969-76 [8797643.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2000 Dec;10(6):372-8 [11147912.001]
  • [Cites] Colorectal Dis. 2007 Mar;9(3):229-34 [17298620.001]
  • [Cites] Ann Surg. 2009 May;249(5):776-82 [19387326.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2009 Aug;19(4):495-9 [19630589.001]
  • [Cites] Surg Endosc. 2009 May;23(5):1138-41 [19263120.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):581-5 [16919110.001]
  • [Cites] Arch Surg. 2009 Feb;144(2):173-9; discussion 179 [19221330.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):270-84 [15711865.001]
  • (PMID = 20174935.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Balaa FK, Gamblin TC, Tsung A, Marsh JW, Geller DA: Right hepatic lobectomy using the staple technique in 101 patients. J Gastrointest Surg; 2008 Feb;12(2):338-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of those with cancer, 78% (69 of 89) had metastatic colorectal cancer, 6% (5 of 89) had metastatic neuroendocrine tumor, 4% (4 of 89) had hepatocellular carcinoma, 4% (4 of 89) had cholangiocarcinoma, and the remaining 8% were other metastatic cancers.
  • Twelve patients (12%) underwent resection for hepatic adenoma or symptomatic benign disease (FNH or hemangioma).
  • Thirty-nine patients (39%) had a nonanatomic wedge resection of a left lobe lesion, 27 patients (27%) had one or more lesions treated with radiofrequency ablation (RFA), and 6 patients (6%) were treated with a synchronous bowel resection.
  • All patients with malignant disease had tumor-free margins at the completion of the procedure.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / surgery. Surgical Stapling
  • [MeSH-minor] Blood Loss, Surgical / statistics & numerical data. Blood Transfusion / statistics & numerical data. Colorectal Neoplasms / pathology. Female. Hemangioma / surgery. Humans. Length of Stay. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1996 Jan;131(1):104-6 [8546569.001]
  • [Cites] Surgery. 1995 Feb;117(2):140-5 [7846617.001]
  • [Cites] Colorectal Dis. 2004 May;6(3):165-70 [15109380.001]
  • [Cites] Am Surg. 2000 Nov;66(11):1037-40 [11090014.001]
  • [Cites] Am J Surg. 1994 Jul;168(1):49-53 [8024098.001]
  • [Cites] J Am Coll Surg. 2001 Aug;193(2):210-22 [11491452.001]
  • [Cites] HPB (Oxford). 2005;7(3):208-13 [18333192.001]
  • [Cites] J Am Coll Surg. 1994 May;178(5):510-1 [8167890.001]
  • [Cites] Liver Int. 2007 Feb;27(1):26-39 [17241378.001]
  • [Cites] Asian J Surg. 2003 Oct;26(4):193-6 [14530102.001]
  • [Cites] Am J Surg. 1989 Nov;158(5):459-60 [2817228.001]
  • [Cites] Surg Obes Relat Dis. 2006 Nov-Dec;2(6):669 [17138242.001]
  • [Cites] Am J Surg. 2004 Feb;187(2):280-4 [14769320.001]
  • [Cites] J Chir (Paris). 1990 Jun-Jul;127(6-7):356-8 [2211893.001]
  • [Cites] Surg Endosc. 2004 Jun;18(6):961-3 [15108116.001]
  • [Cites] Br J Surg. 1991 Jan;78(1):40-1 [1998861.001]
  • [Cites] J Urol. 1993 Jun;149(6):1437-9; discussion 1439-40 [8501782.001]
  • [Cites] ANZ J Surg. 2003 Nov;73(11):922-5 [14616571.001]
  • [Cites] J Am Coll Surg. 1997 Jul;185(1):93-100 [9208969.001]
  • [Cites] Surg Obes Relat Dis. 2006 Jul-Aug;2(4):431-4 [16925374.001]
  • [Cites] Am J Surg. 1996 Oct;172(4):358-62 [8873530.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Sep;18(3):299-303 [10606173.001]
  • [Cites] Am J Surg. 2005 Jul;190(1):23-9 [15972166.001]
  • [Cites] Obes Surg. 2003 Dec;13(6):855-9; discussion 860 [14738669.001]
  • [Cites] Obes Surg. 2006 Dec;16(12):1559-62 [17217629.001]
  • [Cites] Surg Technol Int. 1998;7:43-7 [12721961.001]
  • [Cites] J Invest Surg. 1997 Jan-Apr;10(1-2):59-61 [9100177.001]
  • [Cites] World J Surg. 2006 Mar;30(3):419-30 [16467982.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1697-700 [12820443.001]
  • [Cites] S Afr J Surg. 1992 Jun;30(2):47-8 [1519125.001]
  • (PMID = 17701266.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Zhang W, Hart J, McLeod HL, Wang HL: Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms. Am J Clin Pathol; 2005 Jul;124(1):11-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms.
  • We immunohistochemically examined 75 human colorectal neoplasms (adenoma, 27; adenocarcinoma, 24; neuroendocrine carcinoma, 24) for the expression of activator protein (AP)-1 family proteins.
  • Nuclear and cytoplasmic expression levels of c-Jun and Fra-1 proteins were markedly elevated in adenomas, adenocarcinomas and neuroendocrine carcinomas compared with nonneoplastic colorectal epithelial cells.
  • JunB also was overexpressed in these tumors but with a predominantly cytoplasmic staining pattern.
  • Expression levels of JunD and c-Fos were high in nonneoplastic colorectal epithelial cells and remained so in neoplasms.
  • FosB was undetectable in nonneoplastic and neoplastic colorectal tissues.
  • Hierarchical clustering separated the majority of malignant from benign tumors based on AP-1 expression patterns.
  • AP-1 transcription factor family members are expressed differentially in nonneoplastic and neoplastic colorectal tissues.
  • Up-regulation of c-Jun and Fra-1 is an early event in human colorectal tumorigenesis.
  • Overexpression of Fra-2 may participate in tumor progression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Neuroendocrine / metabolism. Colorectal Neoplasms / metabolism. Epithelial Cells / metabolism. Transcription Factor AP-1 / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923159.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM63340
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-fos; 0 / Proto-Oncogene Proteins c-jun; 0 / Transcription Factor AP-1; 0 / fos-related antigen 1
  •  go-up   go-down


28. Grieco MJ, Shantha Kumara HM, Baxter R, Dujovny N, Kalady MF, Cekic V, Luchtefeld M, Whelan RL: Minimally invasive colorectal resection is associated with a rapid and sustained decrease in plasma levels of epidermal growth factor (EGF) in the colon cancer setting. Surg Endosc; 2010 Oct;24(10):2617-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive colorectal resection is associated with a rapid and sustained decrease in plasma levels of epidermal growth factor (EGF) in the colon cancer setting.
  • BACKGROUND: Epidermal growth factor (EGF) stimulates tumor growth directly via tumor cell EGF receptors or indirectly via its proangiogenic effects.
  • This study's purpose was to determine the impact of minimally invasive colorectal resection (MICR) on postoperative (postop) plasma EGF levels in the colorectal cancer (CRC) and benign disease settings and to see if preoperative (PreOp) EGF levels are altered in cancer patients.
  • METHODS: MICR patients with benign pathology (n = 40) and CRC (n = 48) had blood samples taken PreOp and on postoperative days (POD) 1 and 3.
  • RESULTS: The cancer and benign groups were comparable except for age.
  • The mean PreOp CRC plasma EGF level (122.9 ± 75.9 pg/ml) was significantly higher than that of the benign group (85.3 ± 38.5 pg/ml) (p = 0.015).
  • The benign group's POD3 and POD7-14 EGF levels were significantly lower than the PreOp level; later levels returned toward baseline.
  • MICR is associated with a significant decrease in EGF levels early postop in both cancer and benign settings.
  • Unlike the benign group, EGF blood levels in cancer patients remain low during the second postop month.
  • EGF may have value as a tumor marker.
  • [MeSH-major] Colectomy. Colonic Neoplasms / surgery. Epidermal Growth Factor / blood. Laparoscopy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2011 Aug;25(8):2766-7; author reply 2768 [21416177.001]
  • [Cites] Cancer Res. 1974 Aug;34(8):2109-13 [4842257.001]
  • [Cites] Surg Endosc. 2008 Feb;22(2):287-97 [18204877.001]
  • [Cites] Gynecol Oncol. 1996 Feb;60(2):283-7 [8631552.001]
  • [Cites] Cancer Res. 1988 Sep 15;48(18):5119-23 [3044581.001]
  • [Cites] Cancer Res. 1996 Aug 15;56(16):3823-30 [8706030.001]
  • [Cites] Gut. 1996 Apr;38(4):582-6 [8707092.001]
  • [Cites] Int J Cancer. 1990 Jun 15;45(6):1018-21 [2351482.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3716-25 [15867367.001]
  • [Cites] Ann Surg. 2009 Jun;249(6):973-7 [19474682.001]
  • [Cites] Surgery. 1986 Aug;100(2):273-7 [3738755.001]
  • [Cites] Surgery. 1987 Jul;102(1):71-8 [3495896.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1293-6 [9137488.001]
  • [Cites] Anticancer Res. 1997 Jan-Feb;17(1B):613-9 [9066588.001]
  • [Cites] Surg Endosc. 1999 Mar;13(3):233-5 [10064753.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):162-5 [8391303.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Mol Biol Cell. 1993 Jan;4(1):121-33 [7680247.001]
  • [Cites] Surg Endosc. 1998 Aug;12(8):1035-8 [9685537.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):353-62 [16474912.001]
  • [Cites] Surgery. 2003 Sep;134(3):432-6 [14555930.001]
  • [Cites] J Clin Invest. 1992 Oct;90(4):1352-60 [1401070.001]
  • [Cites] Br J Surg. 1985 Oct;72(10):771-6 [2412626.001]
  • [Cites] Head Neck. 1992 Jan-Feb;14(1):8-13 [1624295.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):186-94 [10638988.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1523-30 [9403702.001]
  • (PMID = 20354877.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


29. Ferroni P, Roselli M, Spila A, D'Alessandro R, Portarena I, Mariotti S, Palmirotta R, Buonomo O, Petrella G, Guadagni F: Serum sE-selectin levels and carcinoembryonic antigen mRNA-expressing cells in peripheral blood as prognostic factors in colorectal cancer patients. Cancer; 2010 Jun 15;116(12):2913-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum sE-selectin levels and carcinoembryonic antigen mRNA-expressing cells in peripheral blood as prognostic factors in colorectal cancer patients.
  • BACKGROUND: This study analyzed the possible prognostic value of presurgical serum soluble (s)E-selectin levels and/or carcinoembryonic antigen (CEA) mRNA positivity in predicting the disease-free survival of colorectal cancer (CRC) patients.
  • METHODS: CEA mRNA (obtained from blood-borne cells by reverse transcriptase-polymerase chain reaction [RT-PCR]), tumor necrosis factor-alpha (TNF-alpha), and sE-selectin levels were analyzed in blood samples obtained from 78 patients with primary (n = 62) or recurrent (n = 16) CRC, 40 patients with benign colorectal (CR) diseases, and 78 controls.
  • Median baseline sE-selectin levels were higher in patients with CRC (43 ng/mL) compared with controls (36 ng/mL) or patients with benign CR diseases (31 ng/mL, P < .001).
  • [MeSH-major] Carcinoembryonic Antigen / genetics. Colorectal Neoplasms / blood. E-Selectin / blood
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. RNA, Messenger / blood. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20336782.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / E-Selectin; 0 / RNA, Messenger
  •  go-up   go-down


30. Kline RC, Bazzett-Matabele LB: Adnexal masses and malignancies of importance to the colorectal surgeon. Clin Colon Rectal Surg; 2010 Jun;23(2):63-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adnexal masses and malignancies of importance to the colorectal surgeon.
  • In this article, the authors review both benign and malignant ovarian masses, as the colorectal surgeon who encounters an adnexal mass at the time of surgery should be aware of the steps necessary for surgical staging and optimal tumor resection.Ovarian tumors-most of which are benign-are divided into three major categories, in order of frequency: epithelial, germ cell, and sex cord-stromal tumors.
  • Nonneoplastic conditions of the ovary that may present as adnexal masses include the following, according to World Health Organization (WHO) classification: pregnancy luteoma, hyperplasia of ovarian stroma, hyperthecosis, massive edema, solitary follicle cysts and corpus luteal cysts, multiple follicle cysts, and endometriosis.Epithelial ovarian tumors arise from the surface epithelium and can be benign or malignant.
  • Germ cell tumors are more likely to appear in females under 20 years, accounting for 70% of ovarian tumors in this age group.
  • Teratomas are the most common germ cell tumors.
  • Malignancies, in addition to malignant teratomas, include dysgerminomas, endodermal sinus tumors, and embryonal carcinomas.
  • The more common sex cord-stromal tumors include granulosa stromal cell tumors, Sertoli-Leydig cell tumors, and gynandroblastomas.Surgical staging and optimal tumor resection are also addressed, with a focus on epithelial malignancies, as they are the most relevant to colorectal surgeons.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):77-81 [11277654.001]
  • [Cites] JAMA. 1983 Dec 9;250(22):3072-6 [6358558.001]
  • [Cites] Am J Obstet Gynecol. 2005 Jul;193(1):30-5 [16021055.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):185-91 [16216320.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):383-90 [17005244.001]
  • [Cites] Obstet Gynecol. 2009 Apr;113(4):775-82 [19305319.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(4):343-51 [2246093.001]
  • [Cites] Curr Top Pathol. 1989;78:85-109 [2651026.001]
  • [Cites] Environ Health Perspect. 1987 Aug;73:15-25 [3665859.001]
  • [Cites] Obstet Gynecol. 1983 Apr;61(4):413-20 [6828269.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):139-44 [2680797.001]
  • [Cites] Obstet Gynecol. 1989 Dec;74(6):921-6 [2685680.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):983-9 [3373267.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):34-7 [12079297.001]
  • (PMID = 21629623.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2967325
  • [Keywords] NOTNLM ; Adnexal masses / ovarian cancer / ovarian cysts
  •  go-up   go-down


31. Koukoutsis I, Pappas A, Karanikas G, Kotzadimitriou K, Chrysikos J, Tzika S, Koronakis N, Karavitis G, Lagoudianakis E, Manouras A: Desmoid tumor of the supraclavicular region: a case report. Cases J; 2009;2:7222
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoid tumor of the supraclavicular region: a case report.
  • Desmoid tumors are rare, benign fibroblastic tumors that are locally infiltrative and can cause extensive morbidity by destruction of adjacent vital structures.
  • Due to the rarity of these tumors, evidence regarding optimal treatment protocols is drawn from case reports and single-arm series with small patient numbers.
  • We report a case of a patient with a desmoid tumor of the left supraclavicular region that was diagnosed and treated in our department and a review of the current literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1390-7 [12663732.001]
  • [Cites] Am J Surg Pathol. 1977 Sep;1(3):255-70 [920873.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1517-23 [10738207.001]
  • [Cites] J Surg Oncol. 2008 May 1;97(6):554-8 [18425778.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4642-60 [17008706.001]
  • [Cites] Orthop Clin North Am. 2006 Jan;37(1):53-63 [16311111.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):158-67 [10458229.001]
  • [Cites] Am J Clin Oncol. 1998 Dec;21(6):584-90 [9856660.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):637-45 [9486614.001]
  • [Cites] Br J Surg. 1996 Nov;83(11):1494-504 [9014661.001]
  • [Cites] Int J Colorectal Dis. 1996;11(4):157-62 [8876270.001]
  • [Cites] Arch Surg. 1989 Feb;124(2):191-6 [2916941.001]
  • [Cites] J Bone Joint Surg Am. 1984 Dec;66(9):1369-74 [6501332.001]
  • [Cites] Am J Clin Pathol. 1982 Jun;77(6):665-73 [7091046.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):181-90 [12562642.001]
  • (PMID = 19829936.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2740207
  •  go-up   go-down


32. Abbasova SG, Vysotskii MM, Ovchinnikova LK, Obusheva MN, Digaeva MA, Britvin TA, Bahoeva KA, Karabekova ZK, Kazantzeva IA, Mamedov UR, Manuchin IB, Davidov MI: Cancer and soluble FAS. Bull Exp Biol Med; 2009 Oct;148(4):638-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A test system developed by the authors was used to measure serum concentrations of soluble Fas in patients with malignant and benign tumors of different location and morphology.
  • It is proven that the concentrations and incidence of detection of soluble Fas in the sera of patients with tumors are significantly higher than in normal subjects.
  • No appreciable differences in the concentrations of soluble Fas were detected in malignant and benign tumors of the mammary gland, bones, ovaries, and adrenals.
  • In thyroid cancer, soluble Fas levels were higher than in benign and hyperplastic processes in this organ.
  • High level of soluble Fas is associated with late stages of the disease (ovarian cancer, cancer of the corpus uteri, adrenocortical and colorectal cancer) and with poor differentiation of the tumor (ovarian cancer and cancer of the corpus uteri), with local metastases (colorectal and adrenocortical cancer), and with tumor invasion into the myometrial tissue, intestinal wall, and adjacent tissues (cancer of the corpus uteri and colorectal cancer).
  • A significantly high level of soluble Fas was detected in colorectal and adrenocortical cancer in the presence of at least 2 local metastases.
  • Soluble Fas levels depended on tumor histogenesis in malignant and benign ovarian tumors.
  • High concentration of soluble Fas was detected in large tumors in patients with ovarian cancer, cancer of the corpus uteri, colorectal cancer, thyroid cancer and adenoma, and in adrenocortical cancer.
  • Initially high levels of soluble Fas are characteristic of patients whose tumors are little sensitive to nonadjuvant radiotherapy.
  • [MeSH-major] Antigens, CD95 / blood. Neoplasms / blood

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20396760.001).
  • [ISSN] 1573-8221
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95
  •  go-up   go-down


33. Shantha Kumara HM, Hoffman A, Kim IY, Feingold D, Dujovny N, Kalady M, Luchtefeld M, Whelan RL: Colorectal resection, both open and laparoscopic-assisted, in patients with benign indications is associated with proangiogenic changes in plasma angiopoietin 1 and 2 levels. Surg Endosc; 2009 Feb;23(2):409-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal resection, both open and laparoscopic-assisted, in patients with benign indications is associated with proangiogenic changes in plasma angiopoietin 1 and 2 levels.
  • INTRODUCTION: Plasma vascular endothelial growth factor (VEGF) levels are increased after surgery and may stimulate tumor growth after cancer resection.
  • This study's purpose was to determine the impact of open and minimally invasive (MIS) colorectal resection (CR) for benign indications on plasma Ang 1 and 2 levels.
  • CONCLUSION: CR for benign pathology results in higher Ang 2 levels, lower Ang 1 levels, and lower Ang 1 to Ang 2 ratios early after surgery.
  • These results, plus the already noted VEGF increases, suggest that surgery results in proangiogenic plasma protein changes that may stimulate tumor growth early after surgery.

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Surg Endosc. 2009 Feb;23(2):416. Kallady, M [corrected to Kalady, M]
  • [Cites] Surg Endosc. 2008 Feb;22(2):287-97 [18204877.001]
  • [Cites] Surg Endosc. 2005 Jan;19(1):55-9 [15531967.001]
  • [Cites] J Pathol. 2004 Sep;204(1):1-10 [15307132.001]
  • [Cites] Clin Chem Lab Med. 1998 Jun;36(6):379-83 [9711425.001]
  • [Cites] Eur J Surg Oncol. 2009 Mar;35(3):295-301 [18782657.001]
  • [Cites] Lab Invest. 1999 Feb;79(2):213-23 [10068209.001]
  • [Cites] Cardiovasc Res. 2001 Feb 16;49(3):659-70 [11166279.001]
  • [Cites] Langenbecks Arch Surg. 2000 Jan;385(1):2-9 [10664112.001]
  • [Cites] World J Surg. 1996 May;20(4):460-4 [8662135.001]
  • [Cites] J Lab Clin Med. 2005 Apr;145(4):194-203 [15962838.001]
  • [Cites] Nat Biotechnol. 1997 Jun;15(6):510 [9181567.001]
  • [Cites] Surg Endosc. 2006 Mar;20(3):482-6 [16432654.001]
  • [Cites] Science. 1998 Oct 16;282(5388):468-71 [9774272.001]
  • [Cites] Biochem Pharmacol. 2001 Feb 1;61(3):253-70 [11172729.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1670-4 [15540297.001]
  • [Cites] Science. 1997 Jul 4;277(5322):55-60 [9204896.001]
  • [Cites] Surgery. 2002 Aug;132(2):186-92 [12219010.001]
  • [Cites] Ann Surg. 2006 Nov;244(5):792-8 [17060773.001]
  • [Cites] Eur Surg Res. 2003 Nov-Dec;35(6):492-6 [14593233.001]
  • [Cites] Lab Invest. 2001 Mar;81(3):361-73 [11310829.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4332-9 [14555503.001]
  • (PMID = 18813991.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ANGPT1 protein, human; 0 / Angiopoietin-1; 0 / Angiopoietin-2
  •  go-up   go-down


34. Rodriguez Ortner E, Hayes RB, Weissfeld J, Gelmann EP: Effect of homeodomain protein NKX3.1 R52C polymorphism on prostate gland size. Urology; 2006 Feb;67(2):311-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A study group of men without prostate cancer from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial was identified who had had at least three annual serial digital rectal examinations by a single examiner.
  • The men in the upper tertile had a greater likelihood of having a clinical history of benign prostatic hyperplasia and more frequent nocturia.
  • The group with prostatic enlargement also had increased clinical benign prostatic hyperplasia and nocturia.
  • [MeSH-major] Genes, Tumor Suppressor. Homeodomain Proteins / genetics. Polymorphism, Genetic. Prostate / pathology. Transcription Factors / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16442598.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / CN25522; United States / NIEHS NIH HHS / ES / ES09888
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / NKX3-1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


35. Honma I, Torigoe T, Hirohashi Y, Kitamura H, Sato E, Masumori N, Tamura Y, Tsukamoto T, Sato N: Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer. J Transl Med; 2009;7:103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High expression levels of AMACR have been described in various cancers, including prostate cancer, colorectal cancer and kidney cancer.
  • In the present study, we examined the induction of AMACR-specific CTLs from prostate cancer patients' peripheral blood mononuclear cells (PBMCs) and determined HLA-A24-restricted CTL epitopes.RT-PCR and immunohistochemical analysis revealed that AMACR was strongly expressed in prostate cancer cell lines and tissues as compared with benign or normal prostate tissues.
  • [MeSH-major] Immunotherapy / methods. Prostatic Neoplasms. Racemases and Epimerases / metabolism
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Line, Tumor. Cytotoxicity, Immunologic. Epitopes. HLA-A Antigens / genetics. HLA-A Antigens / metabolism. HLA-A24 Antigen. Humans. Male. Molecular Sequence Data. Peptides / genetics. Peptides / metabolism. Protein Binding. Tissue Distribution

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Lipid Res. 2000 Nov;41(11):1752-9 [11060344.001]
  • [Cites] J Lipid Res. 2000 Nov;41(11):1890-6 [11060359.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1662-70 [11926890.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2220-6 [11956072.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1731-9 [12060610.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 7):5-11 [12068382.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):841-8 [12213712.001]
  • [Cites] Nat Immunol. 2002 Nov;3(11):999-1005 [12407407.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1588-96 [12459625.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1128-33 [12883245.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):737-45 [14608901.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7365-76 [14612535.001]
  • [Cites] Int J Oncol. 2004 Aug;25(2):487-91 [15254748.001]
  • [Cites] Cancer Immunol Immunother. 2004 Oct;53(10):904-10 [15069585.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4384-9 [3488124.001]
  • [Cites] Prostate. 1994 Aug;25(2):91-6 [7518599.001]
  • [Cites] Br J Urol. 1994 Nov;74(5):609-16 [7530126.001]
  • [Cites] J Urol. 1995 Aug;154(2 Pt 1):407-13 [7541857.001]
  • [Cites] J Immunol. 1995 Nov 1;155(9):4307-12 [7594589.001]
  • [Cites] Urology. 1995 Nov;46(5):681-6; discussion 686-7 [7495121.001]
  • [Cites] Tissue Antigens. 1996 Feb;47(2):93-101 [8851721.001]
  • [Cites] J Immunol. 1997 Apr 1;158(7):3325-34 [9120290.001]
  • [Cites] Immunol Today. 1997 Jun;18(6):267-8 [9190110.001]
  • [Cites] Nat Med. 1998 Mar;4(3):321-7 [9500606.001]
  • [Cites] Int J Cancer. 1999 Jan 18;80(2):219-30 [9935203.001]
  • [Cites] Immunity. 1999 Mar;10(3):281-7 [10204484.001]
  • [Cites] J Urol. 1999 Aug;162(2):293-306 [10411025.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4056-63 [10463607.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1000-9 [15709165.001]
  • [Cites] Prostate. 2006 Feb 1;66(2):211-7 [16173032.001]
  • [Cites] Cancer Immunol Immunother. 2006 Dec;55(12):1515-23 [16622681.001]
  • [Cites] Cancer Immunol Immunother. 2007 May;56(5):689-98 [16937115.001]
  • [Cites] Int J Cancer. 2007 Aug 1;121(3):595-605 [17397028.001]
  • [Cites] J Urol. 2007 Aug;178(2):692-6 [17574613.001]
  • [Cites] J Immunol. 2000 Mar 1;164(5):2565-74 [10679095.001]
  • (PMID = 20003233.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Epitopes; 0 / HLA-A Antigens; 0 / HLA-A24 Antigen; 0 / Peptides; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  • [Other-IDs] NLM/ PMC2797764
  •  go-up   go-down


36. DeFeo EM, Cheng LL: Characterizing human cancer metabolomics with ex vivo 1H HRMAS MRS. Technol Cancer Res Treat; 2010 Aug;9(4):381-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Publications of proton high resolution magic angle spinning (1H HRMAS) magnetic resonance spectroscopy (MRS) and its role in identification of metabolic markers for human cancer reported between 2005 and 2009 are reviewed according the anatomic sites of cancer: lung, breast, prostate, brain, colorectal, and cervical.
  • 1H HRMAS MRS is a valuable tool that can elucidate relevant biological metabolite information that is being used to distinguish cancer from benign tissue, and even classify types of tumors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Magnetic Resonance Spectroscopy. Metabolomics. Neoplasms / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20626203.001).
  • [ISSN] 1533-0338
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA115746; United States / NCI NIH HHS / CA / CA115746-04S2; United States / NCI NIH HHS / CA / CA141139
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, Niki T, Shibahara J, Mori M, Makuuchi M, Hippo Y, Kodama T, Iwanari H, Aburatani H, Fukayama M: The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol; 2005 Dec;18(12):1591-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Then, we evaluated the feasibility of GPC3-immunohistochemistry in the pathological diagnosis of benign and malignant hepatocellular lesions by applying these monoclonal antibodies to formalin-fixed and paraffin-embedded specimens.
  • GPC3 immunoreactivity was detected in only one of 23 metastatic lesions of colorectal carcinoma, and its expression was entirely absent in the liver cell adenoma (0/7), carcinoid tumor (0/1), and cholangiocellular carcinoma (0/16).
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Hepatocellular / diagnosis. Heparan Sulfate Proteoglycans / metabolism. Liver Neoplasms / diagnosis
  • [MeSH-minor] Antibodies, Monoclonal / biosynthesis. Antibodies, Monoclonal / immunology. Cell Line, Tumor. Glypicans. Hepatoblastoma / metabolism. Hepatoblastoma / pathology. Hepatocytes / metabolism. Hepatocytes / pathology. Humans. Liver / embryology. Liver / metabolism. Lung Neoplasms / metabolism. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15920546.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Glypicans; 0 / Heparan Sulfate Proteoglycans
  •  go-up   go-down


38. Hornick JL, Fletcher CD: Intestinal perineuriomas: clinicopathologic definition of a new anatomic subset in a series of 10 cases. Am J Surg Pathol; 2005 Jul;29(7):859-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign peripheral nerve sheath tumors are uncommon in the gastrointestinal tract, and perineuriomas have not previously been reported to occur at this anatomic location.
  • In this study, we analyzed the clinicopathologic and immunohistochemical features of 10 perineuriomas arising in the intestine.
  • Eight of the lesions were intramucosal perineuriomas presenting as small sessile polyps detected during colonoscopy; 6 of these 8 patients were asymptomatic and undergoing colorectal cancer screening.
  • The colonic submucosal tumor was microscopically well circumscribed, whereas the jejunal perineurioma showed focal infiltration through the muscularis propria into the subserosa.
  • The stroma was collagenous in the colonic tumor and predominantly myxoid in the jejunal tumor.
  • All tumors except one were positive for epithelial membrane antigen (EMA); 4 of 10 expressed claudin-1 and 2 of 10 expressed CD34.
  • All tumors were negative for S-100 protein, glial fibrillary acidic protein, neurofilament protein, smooth muscle actin, desmin, caldesmon, KIT, and pan-keratin.
  • Electron microscopy was performed on the tumor lacking EMA expression, revealing typical features of perineurioma, namely, spindle cells with long bipolar cytoplasmic processes and prominent pinocytotic vesicles, surrounded by discontinuous basal lamina.
  • No tumor recurred.
  • In summary, perineuriomas may arise in the intestine, most often as intramucosal lesions detected as colorectal polyps with distinctive histologic features including entrapment of colonic crypts.
  • Distinguishing perineuriomas from other spindle cell neoplasms of the gastrointestinal tract can be facilitated by immunostaining for EMA and claudin-1.
  • [MeSH-major] Intestinal Neoplasms / pathology. Nerve Sheath Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission. Middle Aged. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2006 Oct;30(10):1337-9 [17001168.001]
  • (PMID = 15958849.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 26
  •  go-up   go-down


39. Lewis MR, Deavers MT, Silva EG, Malpica A: Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge. Am J Surg Pathol; 2006 Feb;30(2):177-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge.
  • Ovarian involvement by metastatic colorectal adenocarcinoma, although not an uncommon occurrence, remains a diagnostic challenge.
  • The gross and histologic features of such metastases overlap those of primary ovarian epithelial neoplasms such as endometrioid or mucinous adenocarcinoma.
  • The clinical and pathologic features of 86 cases of metastatic colorectal adenocarcinoma involving the ovary were reviewed.
  • Presenting symptoms included abdominal or pelvic pain (45 cases), rectal bleeding (13 cases), change in bowel habits (20 cases), and vaginal bleeding (5 cases).
  • Many involved ovaries featured smooth capsules without gross evidence of surface involvement by tumor.
  • In general, the tumors had typical histologic features of metastatic colorectal adenocarcinoma, including a garland pattern and dirty necrosis.
  • In 23 cases, foci with a benign or low malignant potential appearance were seen.
  • Immunohistochemical studies showed that 29 of 29 tumors (100%) were positive for CK20; focal CK7 positivity was seen in 5 of 30 cases (17%).
  • Metastatic colorectal adenocarcinoma should be considered in the differential diagnosis of an ovarian mass, even if the mass is large and unilateral or in a young patient, to secure proper treatment of these patients.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434891.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


40. Jost RS, Jost R, Schoch E, Brunner B, Decurtins M, Zollikofer CL: Colorectal stenting: an effective therapy for preoperative and palliative treatment. Cardiovasc Intervent Radiol; 2007 May-Jun;30(3):433-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal stenting: an effective therapy for preoperative and palliative treatment.
  • PURPOSE: To demonstrate the effectiveness of preoperative and palliative colorectal stent placement in acute colonic obstruction.
  • In 59 patients (88%) the obstruction was malignant, while in 8 (12%) it was benign.
  • The improved general condition and adequate bowel cleansing allowed single-stage tumor resection and primary end-to-end anastomosis without complications in 31 cases (86% of all operations), while only 5 patients had colostomies.
  • [MeSH-major] Colonic Diseases / surgery. Colorectal Neoplasms / surgery. Intestinal Obstruction / surgery. Neoadjuvant Therapy. Palliative Care. Stents


41. Hong R, Lim SC: Granular cell tumor of the cecum with extensive hyalinization and calcification: a case report. World J Gastroenterol; 2009 Jul 14;15(26):3315-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumor of the cecum with extensive hyalinization and calcification: a case report.
  • A granular cell tumor (GCT) is a benign neoplasm of unclear histogenesis that is generally believed to be of nerve sheath origin.
  • In addition to the tumor, endoscopic examination revealed the presence of a 5-mm-polyp in the descending colon and multiple tiny polyps in the sigmoid colon and rectum.
  • Histological examination demonstrated a cecal tumor 1.5 cm x 1.0 cm x 0.7 cm with a hard consistency; in cut sections, mixed cells with yellowish and whitish portions were seen.
  • The tumor was located between the mucosa and subserosa, and was composed of plump histiocyte-like tumor cells with abundant granular eosinophilic cytoplasm, which were immunoreactive for S-100 protein, vimentin, neuron-specific enolase, inhibin-alpha and calretinin.
  • The tumor showed extensive hyalinization and focal dystrophic calcification.
  • Extensive hyalinization and calcification showing involution of tumor cells suggest benign clinical behavior of GCT.
  • [MeSH-major] Calcinosis / pathology. Cecum / pathology. Granular Cell Tumor / pathology. Hyalin / metabolism
  • [MeSH-minor] Biomarkers, Tumor. Calbindin 2. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Humans. Male. Middle Aged. Phosphopyruvate Hydratase. S100 Calcium Binding Protein G. S100 Proteins. Vimentin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ugeskr Laeger. 2006 May 22;168(21):2080-1 [16768929.001]
  • [Cites] J Oral Pathol Med. 1997 Apr;26(4):164-9 [9176790.001]
  • [Cites] J Craniofac Surg. 2008 Nov;19(6):1691-4 [19098584.001]
  • [Cites] J Oral Pathol Med. 2009 Jan;38(1):150-9 [19192059.001]
  • [Cites] J Gastroenterol. 2000;35(8):631-4 [10955603.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1200-3 [11688581.001]
  • [Cites] J Gastroenterol. 2003;38(4):385-9 [12743780.001]
  • [Cites] World J Gastroenterol. 2004 Aug 15;10(16):2452-4 [15285042.001]
  • [Cites] Mt Sinai J Med. 1979 Mar-Apr;46(2):195-8 [220528.001]
  • [Cites] J Surg Oncol. 1980;13(4):301-16 [6246310.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Apr;65(4):427-35 [2834681.001]
  • [Cites] Am J Gastroenterol. 1989 Jun;84(6):656-9 [2543214.001]
  • [Cites] Am J Gastroenterol. 1993 Feb;88(2):311-5 [8424442.001]
  • [Cites] Am J Gastroenterol. 1993 Oct;88(10):1785-7 [8213726.001]
  • [Cites] Pathologica. 1995 Apr;87(2):175-8 [8532413.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Dec;80(6):687-97 [8680977.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1997 Jan;94(1):27-32 [9028140.001]
  • [Cites] Turk J Gastroenterol. 2008 Mar;19(1):73-4 [18386247.001]
  • (PMID = 19598311.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / S100 Proteins; 0 / Vimentin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  • [Other-IDs] NLM/ PMC2710791
  •  go-up   go-down


42. Shantha Kumara HM, Cabot JC, Hoffman A, Luchtefeld M, Kalady MF, Hyman N, Feingold D, Baxter R, Whelan RL: Minimally invasive colon resection is associated with a transient increase in plasma sVEGFR1 levels and a decrease in sVEGFR2 levels during the early postoperative period. Surg Endosc; 2009 Apr;23(4):694-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Plasma vascular endothelial growth factor (VEGF) levels are elevated for 2-4 weeks after minimally invasive colorectal resection (MICR).
  • VEGF induces wound and tumor angiogenesis by binding to endothelial cell (EC)-bound VEGF-receptor 1 (VEGFR1) and VEGFR2.
  • The importance of the MICR-related VEGF changes depends on the effect of surgical procedures on sVEGFR1 and sVEGFR2; this study assessed levels of these proteins after MICR for benign indications.
  • [MeSH-minor] Biomarkers / blood. Colorectal Neoplasms / blood. Colorectal Neoplasms / diagnosis. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Follow-Up Studies. Humans. Intraoperative Period. Middle Aged. Postoperative Period. Prognosis. Prospective Studies

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2008 Feb;22(2):287-97 [18204877.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] J Invest Dermatol. 1995 Jul;105(1):44-50 [7615975.001]
  • [Cites] Clin Chem Lab Med. 1998 Jun;36(6):379-83 [9711425.001]
  • [Cites] Eur J Surg Oncol. 2009 Mar;35(3):295-301 [18782657.001]
  • [Cites] J Vasc Surg. 1998 Sep;28(3):535-40 [9737465.001]
  • [Cites] Am J Cardiol. 1999 Feb 1;83(3):337-9 [10072219.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):1011-27 [15585754.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):405-10 [17214745.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):490-8 [10667605.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):14-8 [11857378.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Sci STKE. 2001 Dec 11;2001(112):re21 [11741095.001]
  • [Cites] J Korean Med Sci. 2006 Aug;21(4):608-13 [16891801.001]
  • [Cites] Crit Care Med. 2008 Apr;36(4):1284-9 [18379256.001]
  • [Cites] Clin Chem. 2001 Apr;47(4):617-23 [11274009.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3824-30 [10339489.001]
  • [Cites] Shock. 2008 Apr;29(4):452-7 [18598002.001]
  • [Cites] Ann Surg. 2006 Nov;244(5):792-8 [17060773.001]
  • [Cites] Eur Surg Res. 2003 Nov-Dec;35(6):492-6 [14593233.001]
  • [Cites] Circ Res. 2001 Feb 2;88(2):167-74 [11157668.001]
  • [Cites] Clin Sci (Lond). 1997 May;92(5):453-4 [9176017.001]
  • [Cites] Surg Endosc. 2009 Feb;23(2):409-15 [18813991.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):1931-4 [11929804.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):331-5 [12653578.001]
  • [Cites] Eur Respir J. 2001 Jul;18(1):100-6 [11510779.001]
  • [Cites] FASEB J. 1999 Jan;13(1):9-22 [9872925.001]
  • [Cites] Cancer. 2004 May 1;100(9):1884-91 [15112269.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4332-9 [14555503.001]
  • [Cites] Clin Exp Immunol. 2000 Jan;119(1):182-8 [10606981.001]
  • [Cites] J Exp Med. 1992 Nov 1;176(5):1375-9 [1402682.001]
  • (PMID = 19184203.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


43. Piccolo SR, Frey LJ: Somatic mutation signatures of cancer. AMIA Annu Symp Proc; 2008 Nov 06;:202-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The advancement of cancer diagnosis, prognosis, and treatment would be hastened via a robust method to identify patterns that indicate a tumor's state.
  • Prior research has established that sporadic, colorectal-cancer pathogenesis involves a series of genetic mutations that allow benign polyps to develop and eventually progress to malignant tumors in distinguishable patterns.
  • Our results for colorectal cancer are consistent with what extant biological models as described in the literature.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Pharmacogenomics. 2007 Dec;8(12):1629-33 [18085994.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):318-22 [16421597.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D354-7 [16381885.001]
  • [Cites] Mol Cell Biol. 1992 Mar;12(3):1387-95 [1347643.001]
  • [Cites] N Engl J Med. 2008 Jan 31;358(5):502-11 [18234754.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):769-80 [15510158.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):197-205 [14993901.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 22;104(21):8685-90 [17502601.001]
  • [Cites] Bioinformatics. 2007 Oct 1;23(19):2507-17 [17720704.001]
  • (PMID = 18999255.001).
  • [ISSN] 1942-597X
  • [Journal-full-title] AMIA ... Annual Symposium proceedings. AMIA Symposium
  • [ISO-abbreviation] AMIA Annu Symp Proc
  • [Language] ENG
  • [Grant] United States / NLM NIH HHS / LM / T15 LM007124; United States / NLM NIH HHS / LM / 1T15-LM007124
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2655983
  •  go-up   go-down


44. Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K, Witkin SS, Fishman D, Munkarah A, Morris R, Levin NK, Shirley NN, Tromp G, Abrams J, Draghici S, Tainsky MA: Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res; 2006 Jan 15;66(2):1181-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Protein macroarrays containing 480 of these selected antigen clones revealed 65 clones that interacted with immunoglobulins in sera from 32 ovarian cancer patients but not with sera from 25 healthy women or 14 patients having other benign or malignant gynecologic diseases.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1998 May 29;76(5):652-8 [9610721.001]
  • [Cites] Am J Med. 1998 Apr;104(4):374-80 [9576412.001]
  • [Cites] Gynecol Oncol. 1999 Jan;72(1):76-81 [9889034.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2158-66 [10090922.001]
  • [Cites] Int J Cancer. 1999 Oct 22;84(5):506-10 [10502728.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):456-64 [10508479.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Sep;5(5):735-43 [16149876.001]
  • [Cites] Adv Exp Med Biol. 1999;472:187-98 [10736626.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3629-35 [10999755.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4060-5 [11274429.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2055-61 [11280766.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3806-9 [11325856.001]
  • [Cites] Oncogene. 2001 Jul 12;20(31):4107-14 [11464277.001]
  • [Cites] Gene. 2001 Aug 22;274(1-2):67-75 [11674998.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7908-12 [11691811.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1570-7 [11896106.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):418-23 [11992411.001]
  • [Cites] Biochem Biophys Res Commun. 2002 May 24;293(5):1544-9 [12054692.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4041-7 [12124339.001]
  • [Cites] Lancet. 2002 Jul 13;360(9327):169; author reply 170-1 [12126842.001]
  • [Cites] Lancet. 2002 Jul 13;360(9327):169-70; author reply 170-1 [12126843.001]
  • [Cites] Lancet. 2002 Jul 13;360(9327):170; author reply 170-1 [12126844.001]
  • [Cites] Lancet. 2002 Jul 13;360(9327):170; author reply 170-1 [12126845.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Feb;36(2):198-204 [12508248.001]
  • [Cites] Cancer Immun. 2001 Mar 30;1:4 [12747765.001]
  • [Cites] Biometrics. 2003 Mar;59(1):133-42 [12762450.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1423-9 [14508829.001]
  • [Cites] Biometrics. 2003 Sep;59(3):614-23 [14601762.001]
  • [Cites] Nat Genet. 2004 Jan;36(1):40-5 [14702039.001]
  • [Cites] Int J Colorectal Dis. 2004 Mar;19(2):114-20 [14634775.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):353-6 [14996856.001]
  • [Cites] Clin Chem. 1986 Nov;32(11):2110-1 [3465487.001]
  • [Cites] Jpn J Surg. 1986 Sep;16(5):305-10 [3467109.001]
  • [Cites] Mol Immunol. 1986 Jul;23(7):709-15 [2432410.001]
  • [Cites] Int J Cancer. 1988 Nov 15;42(5):677-80 [3182103.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5472-6 [1608957.001]
  • [Cites] Hum Mol Genet. 1993 Mar;2(3):283-7 [8388766.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):16-20 [7505195.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3 [8524854.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1501-9 [8608535.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):725-9 [8642276.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8 [9050879.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3363-7 [9363867.001]
  • [Cites] Int J Cancer. 1998 Sep 25;78(1):27-32 [9724090.001]
  • (PMID = 16424057.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA100740; United States / NCI NIH HHS / CA / CA022453-24; United States / NHGRI NIH HHS / HG / HG003491-01A1; United States / NHGRI NIH HHS / HG / R01 HG003491-01A1; United States / NINDS NIH HHS / NS / NS045207-01; United States / NCI NIH HHS / CA / CA 100740; United States / NINDS NIH HHS / NS / R01 NS045207-01; United States / NCI NIH HHS / CA / CA100740-01; United States / NINDS NIH HHS / NS / R01 NS045207; United States / NCI NIH HHS / CA / P30 CA022453; United States / NHGRI NIH HHS / HG / 1R01 HG 003491-01; United States / NHGRI NIH HHS / HG / R01 HG003491; United States / NINDS NIH HHS / NS / 1R01 NS 045207-01; United States / NCI NIH HHS / CA / P30 CA022453-24; United States / NCI NIH HHS / CA / P30 CA 022453; United States / NCI NIH HHS / CA / R21 CA100740-01; United States / NCI NIH HHS / CA / R33 CA100740
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Peptide Library
  • [Other-IDs] NLM/ NIHMS48954; NLM/ PMC2546578
  •  go-up   go-down


45. Lin LQ, Zhang CP, Zhao JL, Liu Y, Zhang SJ, Jin JC, Wang L, Liu JR: Differential expression of proteomics models of colorectal cancer, colorectal benign disease and healthy controls. Proteome Sci; 2010 Mar 25;8:16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of proteomics models of colorectal cancer, colorectal benign disease and healthy controls.
  • BACKGROUND: Colorectal cancer (CRC) is often diagnosed at a late stage with concomitant poor prognosis.
  • The hypersensitive analytical technique of proteomics can detect molecular changes before the tumor is palpable.
  • The protein chips have established the expression of tumor protein in the serum specimens and become the newly discovered markers for tumor diagnosis.
  • The objective of this study was to find new markers of the diagnosis among groups of CRC, colorectal benign diseases (CBD) and healthy controls.
  • One hundred serum samples, including 52 cases of colorectal cancer, 27 cases of colorectal benign disease, and 21 cases of healthy controls, were examined by SELDI-TOF-MS with WCX2 protein-chips.
  • CONCLUSIONS: The SELDI-TOF-MS is a useful tool to help diagnose colorectal cancer, especially during the early stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Cancer Biol. 2005 Dec;15(6):484-93 [16055342.001]
  • [Cites] Clin Chem. 2003 May;49(5):752-60 [12709366.001]
  • [Cites] Arch Pathol Lab Med. 2007 Jan;131(1):50-6 [17227123.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Dec;24(4):505-14 [16471312.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Exp Oncol. 2006 Dec;28(4):282-7 [17285111.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1898-905 [16755300.001]
  • [Cites] Proteome Sci. 2009;7:34 [19728888.001]
  • [Cites] Mol Cancer. 2007;6:25 [17407558.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3609-14 [12097261.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4656-61 [12907646.001]
  • [Cites] Proteome Sci. 2008;6:19 [18558005.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):267-79 [12781425.001]
  • [Cites] BMC Cancer. 2009;9:287 [19689818.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1491-502 [11290567.001]
  • [Cites] Technol Cancer Res Treat. 2002 Aug;1(4):231-6 [12625781.001]
  • [Cites] Biotechniques. 2000 Nov;29(5):1066-70 [11084869.001]
  • [Cites] Int J Colorectal Dis. 1989 Dec;4(4):230-3 [2693562.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):26-30 [16395400.001]
  • (PMID = 20334691.001).
  • [ISSN] 1477-5956
  • [Journal-full-title] Proteome science
  • [ISO-abbreviation] Proteome Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2862023
  •  go-up   go-down


46. Belizon A, Balik E, Horst PK, Shantha Kumara HM, Nasar A, Whelan RL: Platelet-derived growth factor (subtype BB) is elevated in patients with colorectal carcinoma. Dis Colon Rectum; 2009 Jun;52(6):1166-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platelet-derived growth factor (subtype BB) is elevated in patients with colorectal carcinoma.
  • PURPOSE: Platelet-derived growth factor-BB plays a role in the development of vascular and lymphatic vessels in tumors.
  • In this study plasma levels of platelet-derived growth factor-BB were assessed preoperatively in patients with adenomas and colorectal cancer to determine whether platelet-derived growth factor-BB is a useful marker or prognostic indicator.
  • METHODS: Patients with adenomas and colorectal cancer undergoing resection were assessed.
  • RESULTS: One hundred seventy-nine patients were studied (91 with colorectal cancer, 88 with adenomas).
  • Preoperative colorectal cancer platelet-derived growth factor-BB levels were higher (1,771.1 pg/ml; confidence intervals, 1,429-2,065) than in the benign neoplasm group (1083 pg/ml; confidence intervals, 933-1,192, P < 0.001).
  • In patients with colorectal cancer, a direct relationship was noted between platelet-derived growth factor-BB levels and disease severity.
  • CONCLUSION: Platelet-derived growth factor-BB levels were greater in patients with colorectal cancer (vs. patients with adenoma) and rose with increasing disease severity.
  • [MeSH-major] Adenoma / blood. Colorectal Neoplasms / blood. Platelet-Derived Growth Factor / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Chi-Square Distribution. Enzyme-Linked Immunosorbent Assay. Female. Humans. Logistic Models. Male. Proto-Oncogene Proteins c-sis. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581863.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Platelet-Derived Growth Factor; 0 / Proto-Oncogene Proteins c-sis; 0 / platelet-derived growth factor BB
  •  go-up   go-down


47. Koch M, Kienle P, Logan E, Antolovic D, Galindo L, Schmitz-Winnenthal FH, Schmidt J, Herfarth C, Weitz J: Detection of disseminated tumor cells in liver biopsies of colorectal cancer patients is not associated with a worse prognosis. Ann Surg Oncol; 2007 Feb;14(2):810-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of disseminated tumor cells in liver biopsies of colorectal cancer patients is not associated with a worse prognosis.
  • BACKGROUND: Liver metastases occur frequently in colorectal cancer and are probably caused by disseminated tumor cells having been trapped in the liver.
  • The prognostic significance of hematogenous tumor cell dissemination has already been demonstrated for blood and bone marrow of patients with colorectal cancer.
  • The aim of this study was to investigate the frequency and prognostic significance of disseminated tumor cells in liver biopsies of colorectal cancer patients.
  • METHODS: Liver biopsies from 100 patients with UICC stage I-III colorectal cancer were taken prospectively during resection of the primary tumor.
  • Liver biopsies obtained from 16 patients with benign gastrointestinal diseases served as negative controls.
  • RESULTS: Disseminated tumor cells were detected in liver samples of 10/100 (10%) patients with UICC stage I-III colorectal cancer.
  • Liver specimens from all seven patients with liver cirrhosis were CK 20-positive, whereas 16 patients with other benign gastrointestinal diseases were all CK 20-negative.
  • There was no correlation between tumor cell detection in liver biopsies and survival of the patients.
  • CONCLUSIONS: This study demonstrates that detection of disseminated tumor cells in liver samples from patients with UICC stage I-III colorectal cancer has no prognostic influence.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver / pathology. Liver Neoplasms / secondary. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Aged. Biopsy. Female. Humans. Keratin-20 / analysis. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies


48. Gelos M, Hinderberger D, Welsing E, Belting J, Schnurr K, Mann B: Analysis of albumin fatty acid binding capacity in patients with benign and malignant colorectal diseases using electron spin resonance (ESR) spectroscopy. Int J Colorectal Dis; 2010 Jan;25(1):119-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of albumin fatty acid binding capacity in patients with benign and malignant colorectal diseases using electron spin resonance (ESR) spectroscopy.
  • INTRODUCTION: In colorectal cancer (CRC), no biological marker is known that could serve both as a marker for detection and prognosis.
  • OBJECTIVE: The aim of this study was to examine whether the FA binding to albumin is detectably and significantly altered in CRC patients when compared with patients having benign colorectal diseases.
  • MATERIALS AND METHODS: One hundred four patients operatively or endoscopically treated for CRC, sigmoid diverticulitis, or a colorectal adenoma were examined before procedure.
  • RESULTS AND DISCUSSIONS: Patients with CRC showed significantly lower DR values (DR, -0.09 +/- 0.98 vs. 0.61 +/- 1.43) than patients with benign colorectal diseases, consistent with a change of conformation and transport function of albumin in CRC.
  • Within the CRC group, with advanced tumor stage, the difference in DR values increased.
  • Furthermore, a correlation with advanced tumor stage can be established.
  • [MeSH-major] Colorectal Neoplasms / metabolism. Electron Spin Resonance Spectroscopy / methods. Fatty Acids / metabolism. Serum Albumin / metabolism
  • [MeSH-minor] Aged. Demography. Endoscopy. Female. Humans. Male. Neoplasm Staging. Postoperative Care. Preoperative Care. Protein Binding

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2003 Oct 30;425(6961):905 [14586448.001]
  • [Cites] Transfus Apher Sci. 2002 Oct;27(2):129-35 [12350048.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1935-53 [17932341.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2746-8 [15987925.001]
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1348-60 [17512720.001]
  • [Cites] Biol Pharm Bull. 2002 Jun;25(6):695-704 [12081132.001]
  • [Cites] Cancer Invest. 2007 Sep;25(6):378-83 [17882647.001]
  • [Cites] Nat Struct Biol. 1998 Sep;5(9):827-35 [9731778.001]
  • [Cites] Bull Exp Biol Med. 2004 Aug;138(2):177-8 [15662465.001]
  • [Cites] Biochim Biophys Acta. 1990 Dec 6;1036(3):228-36 [2175216.001]
  • [Cites] Clin Chem. 2006 Nov;52(11):2129-34 [16990414.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Dis Markers. 2003-2004;19(1):1-10 [14757941.001]
  • [Cites] Biochim Biophys Acta. 2000 Jun 1;1466(1-2):350-60 [10825455.001]
  • [Cites] J Mol Biol. 2006 Aug 11;361(2):336-51 [16844140.001]
  • [Cites] Gastroenterology. 2008 Aug;135(2):380-99 [18582467.001]
  • [Cites] Angew Chem Int Ed Engl. 2004 Sep 6;43(35):4616-21 [15317002.001]
  • (PMID = 19644694.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Serum Albumin
  •  go-up   go-down


49. Belinsky GS, Claffey KP, Nambiar PR, Guda K, Rosenberg DW: Vascular endothelial growth factor and enhanced angiogenesis do not promote metastatic conversion of a newly established azoxymethane-induced colon cancer cell line. Mol Carcinog; 2005 Jun;43(2):65-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The organo-specific carcinogen, azoxymethane (AOM), produces colon tumors in mice that share many pathological features with sporadic human colorectal cancer (CRC).
  • To assess the role of the microenvironment in preventing the invasive phenotype, multiple benign in situ adenocarcinomas were harvested from AOM-treated mice and cultured in vitro.
  • However, tumor cell growth was extremely limiting under standard culturing conditions.
  • Thus, we injected tumor cells directly into nude mice and performed two serial transplants, and successfully explanted a rapidly growing epithelial tumor cell line (AJ02nm(0)).
  • When injected subcutaneously (sc) into nude mice, AJ02nm(0) cells formed well-differentiated adenocarcinomas with minimal tumor invasive capacity.
  • AJ02nm-VEGF cells produced rapidly growing tumors in nude mice that exhibited extensive pseudo-epithelial ductal architecture and supporting vasculature, but without increased invasive potential compared to controls.
  • [MeSH-major] Colonic Neoplasms / blood supply. Neovascularization, Pathologic / physiopathology. Vascular Endothelial Growth Factor A / physiology
  • [MeSH-minor] Animals. Antigens, CD31 / analysis. Apoptosis. Cell Division. Cell Line, Tumor. Colorectal Neoplasms / blood supply. Colorectal Neoplasms / pathology. Karyotyping. Male. Mice. Mice, Inbred A. Mice, Nude. Neoplasm Transplantation. Transfection

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15768385.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 81428
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


50. Korsisaari N, Kasman IM, Forrest WF, Pal N, Bai W, Fuh G, Peale FV, Smits R, Ferrara N: Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proc Natl Acad Sci U S A; 2007 Jun 19;104(25):10625-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anti-VEGF-A monoclonal antibodies, in combination with chemotherapy, result in a survival benefit in patients with metastatic colorectal and non-small cell lung cancer, but little is known regarding the impact of anti-VEGF-A therapy on benign or premalignant tumors.
  • To investigate whether tumor growth in Apc+/min mice is mediated by VEGF-A-dependent angiogenesis, we used two independent approaches to inhibit VEGF-A: monotherapy with a monoclonal antibody (Mab) targeting VEGF-A and genetic deletion of VEGF-A selectively in intestinal epithelial cells.
  • Short-term (3 or 6 weeks) treatment with anti-VEGF-A Mab G6-31 resulted in a nearly complete suppression of adenoma growth throughout the small intestine.
  • Deletion of VEGF-A in intestinal epithelial cells of Apc+/min mice yielded a significant inhibition of tumor growth, albeit of lesser magnitude than that resulting from Mab G6-31 administration.
  • These results establish that inhibition of VEGF-A signaling is sufficient for tumor growth cessation and confers a long-term survival benefit in an intestinal adenoma model.
  • [MeSH-minor] Adenoma / blood supply. Adenoma / genetics. Adenoma / immunology. Adenoma / therapy. Animals. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacology. Gene Deletion. In Situ Hybridization. Intestinal Neoplasms / blood supply. Intestinal Neoplasms / genetics. Intestinal Neoplasms / immunology. Intestinal Neoplasms / therapy. Mice. Mice, Inbred C57BL. Signal Transduction / immunology. Survival Analysis. Time Factors

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5209-18 [10537299.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):316-25 [16507828.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5040-4 [11016626.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6253-8 [11103779.001]
  • [Cites] Cancer Lett. 2002 Jan 25;175(2):157-63 [11741743.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):506-11 [11809702.001]
  • [Cites] Dev Dyn. 2002 May;224(1):90-102 [11984877.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1351-9 [12151354.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8 [12177445.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33275-83 [12065599.001]
  • [Cites] Expert Opin Investig Drugs. 2002 Dec;11(12):1715-36 [12457433.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):391-400 [12750232.001]
  • [Cites] Br J Cancer. 2003 May 6;88(9):1445-52 [12778076.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Curr Biol. 2003 Sep 30;13(19):1721-7 [14521839.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] J Exp Med. 1972 Aug 1;136(2):261-76 [5043412.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Dec;82(24):8488-92 [3909146.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Science. 1992 May 1;256(5057):668-70 [1350108.001]
  • [Cites] Development. 1992 Jul;115(3):717-28 [1425351.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]
  • [Cites] J Clin Invest. 1995 Apr;95(4):1789-97 [7535799.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2556-60 [8653697.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Nature. 1997 Apr 17;386(6626):671-4 [9109485.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4267-73 [9331087.001]
  • [Cites] Prostate. 1998 Apr 1;35(1):1-10 [9537593.001]
  • [Cites] Carcinogenesis. 1999 Jan;20(1):51-8 [9934849.001]
  • [Cites] Development. 1999 Mar;126(6):1149-59 [10021335.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4389-400 [15899831.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):967-74 [16355214.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):951-61 [16278208.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):549-60 [16336962.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1710-7 [16685275.001]
  • [Cites] Carcinogenesis. 2006 Oct;27(10):2133-9 [16782971.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3478-83 [17360669.001]
  • [Cites] J Clin Invest. 2000 Jun;105(11):1589-94 [10841517.001]
  • (PMID = 17553957.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC1888576
  •  go-up   go-down


51. Chang X, Han J, Pang L, Zhao Y, Yang Y, Shen Z: Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer; 2009;9:40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased PADI4 expression in blood and tissues of patients with malignant tumors.
  • METHODS: Expression of PADI4 was investigated in various tumors and non-tumor tissues (n = 1673) as well as in A549, SKOV3 and U937 tumor cell lines by immunohistochemistry, real-time PCR, and western blot.
  • Levels of PADI4 and citrullinated antithrombin (cAT) were investigated in the blood of patients with various tumors by ELISA (n = 1121).
  • RESULTS: Immunohistochemistry detected significant PADI4 expression in various malignancies including breast carcinomas, lung adenocarcinomas, hepatocellular carcinomas, esophageal squamous cancer cells, colorectal adenocarcinomas, renal cancer cells, ovarian adenocarcinomas, endometrial carcinomas, uterine adenocarcinomas, bladder carcinomas, chondromas, as well as other metastatic carcinomas.
  • However, PADI4 expression was not observed in benign leiomyomas of stomach, uterine myomas, endometrial hyperplasias, cervical polyps, teratomas, hydatidiform moles, trophoblastic cell hyperplasias, hyroid adenomas, hemangiomas, lymph hyperplasias, schwannomas, neurofibromas, lipomas, and cavernous hemangiomas of the liver.
  • Additionally, PADI4 expression was not detected in non-tumor tissues including cholecystitis, cervicitis and synovitis of osteoarthritis, except in certain acutely inflamed tissues such as in gastritis and appendicitis.
  • Furthermore, western blot analysis detected PADI4 expression in cultured tumor cell lines.
  • ELISA detected increased PADI4 and cAT levels in the blood of patients with various malignant tumors compared to those in patients with chronic inflammation and benign tumors.
  • Additionally, PADI4 and cAT levels were significantly associated with higher levels of known tumor markers.
  • CONCLUSION: Our results suggest that PADI4 expression is increased in the blood and tissues of many malignant tumors, a finding useful for further understanding of tumorigenesis.
  • [MeSH-major] Hydrolases / metabolism. Neoplasm Proteins / metabolism. Neoplasms / metabolism
  • [MeSH-minor] Antithrombins / metabolism. Blotting, Western. Cell Line, Tumor. Citrulline / metabolism. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Immunoprecipitation. Male. Polymerase Chain Reaction / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 1998 May-Jun;84(3):364-7 [9678618.001]
  • [Cites] Pathologe. 1996 Nov;17(6):425-32 [9082363.001]
  • [Cites] J Cell Mol Med. 2004 Oct-Dec;8(4):498-508 [15601578.001]
  • [Cites] Folia Histochem Cytobiol. 2004;42(4):235-40 [15704650.001]
  • [Cites] Rheumatology (Oxford). 2005 Mar;44(3):293-8 [15561738.001]
  • [Cites] Semin Cancer Biol. 2005 Aug;15(4):309-18 [15907383.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2936-42 [16365013.001]
  • [Cites] Mol Carcinog. 2006 Mar;45(3):183-96 [16355400.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1261-9 [16799479.001]
  • [Cites] Mol Endocrinol. 2007 Jul;21(7):1617-29 [17456793.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):76-80 [17826626.001]
  • [Cites] World J Gastroenterol. 2008 Mar 21;14(11):1682-9 [18350599.001]
  • [Cites] Histochem Cell Biol. 2008 Jun;129(6):705-33 [18461349.001]
  • [Cites] Endocr Relat Cancer. 2008 Jun;15(2):475-83 [18509000.001]
  • [Cites] J Biol Chem. 2008 Jul 18;283(29):20060-8 [18499678.001]
  • [Cites] Mol Cell Biol. 2008 Aug;28(15):4745-58 [18505818.001]
  • [Cites] Adv Exp Med Biol. 2008;630:112-32 [18637488.001]
  • [Cites] Histopathology. 2001 Jan;38(1):62-7 [11135048.001]
  • [Cites] Cell Death Differ. 2002 May;9(5):486-92 [11973607.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):173-7 [12023846.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):201-7 [12023851.001]
  • [Cites] Nat Genet. 2003 Aug;34(4):395-402 [12833157.001]
  • [Cites] Best Pract Res Clin Anaesthesiol. 2004 Sep;18(3):385-405 [15212335.001]
  • [Cites] Cell. 2004 Sep 3;118(5):545-53 [15339660.001]
  • [Cites] Anticancer Res. 1990 May-Jun;10(3):579-82 [2114816.001]
  • [Cites] APMIS. 1991 Nov;99(11):981-8 [1720319.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(3):209-15 [1384221.001]
  • [Cites] Int J Cancer. 1993 Jul 9;54(5):793-806 [7686887.001]
  • [Cites] Thromb Haemost. 1998 Nov;80(5):767-72 [9843169.001]
  • (PMID = 19183436.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antithrombins; 0 / Neoplasm Proteins; 29VT07BGDA / Citrulline; EC 3.- / Hydrolases; EC 3.5.3.15 / peptidylarginine deiminase type IV
  • [Other-IDs] NLM/ PMC2637889
  •  go-up   go-down


52. Grossmann I, Avenarius JK, Mastboom WJ, Klaase JM: Preoperative staging with chest CT in patients with colorectal carcinoma: not as a routine procedure. Ann Surg Oncol; 2010 Aug;17(8):2045-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative staging with chest CT in patients with colorectal carcinoma: not as a routine procedure.
  • BACKGROUND: Preoperative staging of patients with colorectal carcinoma (CRC) has the potential benefit of altering treatment options when metastases are present.
  • MATERIALS AND METHODS: All patients who undergo colorectal surgery in our hospital are prospectively registered, including patient, treatment, and histopathological characteristics; outcome; and follow-up.
  • These were diagnosed during follow-up as true metastases (n = 8), bronchus carcinoma (n = 2), benign lesions (n = 25), and remaining unknown (n = 15).
  • In none of the patients the treatment plan for the primary tumor was changed based on the staging chest CT.
  • [MeSH-major] Colorectal Neoplasms / pathology. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Neoplasm Staging / methods. Preoperative Care. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 2007 Jul-Aug;31(4):569-71 [17882033.001]
  • [Cites] Onkologie. 2007 Mar;30(3):141-5 [17341902.001]
  • [Cites] Ann R Coll Surg Engl. 2007 Nov;89(8):744-8 [17999813.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):1026-32 [19184237.001]
  • [Cites] Colorectal Dis. 2009 Jul;11(6):592-600 [18624816.001]
  • [Cites] Colorectal Dis. 2007 Nov;9(9):816-8 [17931171.001]
  • [Cites] Radiology. 2001 Jan;218(1):55-60 [11152779.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 May;21(5):906-12 [12062285.001]
  • [Cites] Ann Surg Oncol. 1998 Jan-Feb;5(1):9-15 [9524701.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):229-35 [10421258.001]
  • [Cites] Annu Rev Med. 2005;56:139-56 [15660506.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2005 Jan;53(1):22-8 [15724498.001]
  • [Cites] Ann R Coll Surg Engl. 2005 Sep;87(5):331-3 [16176690.001]
  • [Cites] Radiat Med. 2005 Sep;23(6):418-26 [16389984.001]
  • [Cites] Surgery. 2007 Jan;141(1):67-75 [17188169.001]
  • [CommentIn] Ann Surg Oncol. 2011 Dec;18 Suppl 3:S224-5; author reply S226-7 [20839065.001]
  • (PMID = 20151212.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2899025
  •  go-up   go-down


53. Roessler M, Rollinger W, Mantovani-Endl L, Hagmann ML, Palme S, Berndt P, Engel AM, Pfeffer M, Karl J, Bodenmüller H, Rüschoff J, Henkel T, Rohr G, Rossol S, Rösch W, Langen H, Zolg W, Tacke M: Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol Cell Proteomics; 2006 Nov;5(11):2092-101
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis.
  • The purpose of this study was to identify and validate novel serological protein biomarkers of human colorectal cancer (CRC).
  • M., Schneidinger, B., Pfeffer, M., Andres, H., Karl, J., Bodenmuller, H., Ruschoff, J., Henkel, T., Rohr, G., Rossol, S., Rosch, W., Langen, H., Zolg, W., and Tacke, M. (2005) Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin.
  • The PSME3-containing spot on tumor gels showed no visible difference to the corresponding spot on matched control gels.
  • MS analysis revealed the presence of two proteins, PSME3 and annexin 4 (ANXA4) in one and the same spot on tumor gels, whereas the matched spot contained only one protein, ANXA4, on control gels.
  • Finally by developing a highly sensitive immunoassay, PSME3 could be detected in human sera and was significantly elevated in CRC patients compared with healthy donors and patients with benign bowel disease.
  • We propose that PSME3 be considered a novel serum tumor marker for CRC that may have significance in the detection and in the management of patients with this disease.
  • [MeSH-major] Autoantigens / blood. Biomarkers, Tumor / blood. Colorectal Neoplasms / diagnosis. Electrophoresis, Gel, Two-Dimensional. Mass Spectrometry / methods. Proteasome Endopeptidase Complex / blood


54. Wierzbicki PM, Adrych K, Kartanowicz D, Dobrowolski S, Stanislawowski M, Chybicki J, Godlewski J, Korybalski B, Smoczynski M, Kmiec Z: Fragile histidine triad (FHIT) gene is overexpressed in colorectal cancer. J Physiol Pharmacol; 2009 Oct;60 Suppl 4:63-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fragile histidine triad (FHIT) gene is overexpressed in colorectal cancer.
  • AIM: To investigate loss of heterozygosity (LOH) at FRA3B, expression of FHIT gene at the mRNA and protein levels in sporadic colorectal carcinoma (CRC) and benign colon adenoma.
  • MATERIALS AND METHODS: FHIT mRNA was quantified by the validated realtime PCR (QPCR) in tumor samples of 84 CRC patients and mucosal biopsies of 15 adenomas, in comparison to 37 control patients, whereas subgroup of 57 CRC, 10 adenoma and 10 control cases were selected for immunohistochemical (IHC) detection of the native FHIT protein and LOH determination at FRA3B.
  • CONCLUSION: Our data suggest that reduction or absence of the FHIT gene expression is not a prerequisite for colorectal cancer development and progression.
  • [MeSH-major] Acid Anhydride Hydrolases / biosynthesis. Adenoma / metabolism. Colorectal Neoplasms / metabolism. Neoplasm Proteins / biosynthesis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20083853.001).
  • [ISSN] 1899-1505
  • [Journal-full-title] Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • [ISO-abbreviation] J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / fragile histidine triad protein; 63231-63-0 / RNA; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


55. Falguières T, Maak M, von Weyhern C, Sarr M, Sastre X, Poupon MF, Robine S, Johannes L, Janssen KP: Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool. Mol Cancer Ther; 2008 Aug;7(8):2498-508
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool.
  • The targeting of solid tumors requires delivery tools that resist intracellular and extracellular inactivation, and that are taken up specifically by tumor cells.
  • We have shown previously that the recombinant nontoxic B-subunit of Shiga toxin (STxB) can serve as a delivery tool to target digestive tumors in animal models.
  • The aim of this study was to expand these experiments to human colorectal cancer.
  • Tissue samples of normal colon, benign adenomas, colorectal carcinomas, and liver metastases from 111 patients were obtained for the quantification of the expression of the cellular STxB receptor, the glycosphingolipid globotriaosyl ceramide (Gb(3) or CD77).
  • We found that compared with normal tissue, the expression of Gb(3) was strongly increased in colorectal adenocarcinomas and their metastases, but not in benign adenomas.
  • Of a given tumor sample, on average, 80% of the cells could visibly bind STxB, and upon incubation at 37 degrees C, STxB was transported to the Golgi apparatus, following the retrograde route.
  • This STxB-specific intracellular targeting allows the molecule to avoid recycling and degradation, and STxB could consequently be detected on tumor cells even 5 days after initial uptake.
  • In conclusion, the targeting properties of STxB could be diverted for the delivery of contrast agents to human colorectal tumors and their metastases, whose early detection and specific targeting remains one of the principal challenges in oncology.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / biosynthesis. Colorectal Neoplasms / therapy. Intestines / microbiology. Shiga Toxins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromatography, Thin Layer. Female. Humans. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. Trihexosylceramides / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18687997.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Gb3 antigen; 0 / Shiga Toxins; 0 / Trihexosylceramides; 0 / stxB toxin; 71965-57-6 / globotriaosylceramide
  •  go-up   go-down


56. Gao Y, Zhang B: [Expression of TEIF protein in colorectal tumors and its correlation with centrosome abnormality]. Ai Zheng; 2009 Dec;28(12):1277-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of TEIF protein in colorectal tumors and its correlation with centrosome abnormality].
  • BACKGROUND AND OBJECTIVE: Telomerase transcriptional elements-interacting factor (TEIF) gene found recently by our research group is a transcription factor of a kind of human telomerase reverse transcriptase (hTERT) gene, and expresses in many kinds of tumor tissues.
  • This study was to evaluate the expression of TEIF protein in human colorectal tumors and to explore its correlation with centrosome abnormality.
  • METHODS: The expression of TEIF in 10 specimens of normal intestinal mucosa tissue, 30 specimens of colorectal cancer, and 54 specimens of colorectal adenoma was detected by immunohistochemistry.
  • RESULTS: Immunohistochemistry results showed that the differences of TEIF protein expression between the normal group and each tumor groups were statistically significant (P<0.01), and the difference of TEIF protein expression between the malignant tumor group and the benign group was not significant (P>0.05).
  • Immunofluorescence results showed that centrosome amplification-positive rate was significantly higher in the colorectal cancer group than in the normal group or the adenoma group (both P<0.01); the difference of the centrosome amplification positive rate between Grade I adenoma and Grade III adenoma was statistically significant (P<0.05), and the differences of the centrosome amplification positive rate between Grade II adenoma and Grade I or III adenoma were statistically significant (P>0.05).
  • CONCLUSIONS: TEIF protein and centrosome amplification is commonly found in colorectal tumors.
  • The expression level of TEIF is related to tumor histological grade and malignant degree.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Centrosome / pathology. Colorectal Neoplasms / metabolism. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958622.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Transcription Factors; 0 / Tubulin; EC 2.7.1.- / SCYL1 protein, human
  •  go-up   go-down


57. Wang W, Feng B, Li X, Yin P, Gao P, Zhao X, Lu X, Zheng M, Xu G: Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography-mass spectrometry. Mol Biosyst; 2010 Oct;6(10):1947-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography-mass spectrometry.
  • Colorectal carcinoma (CRC) is the third most commonly encountered cancer and fourth cause of cancer-associated death worldwide.
  • In this study both ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) and online affinity solid phase extraction-high performance liquid chromatography (SPE-HPLC) were used to analyze the urinary metabolites from 34 healthy volunteers, 34 benign colorectal tumor and 50 colorectal carcinoma patients to produce comprehensive metabolic profiling data.
  • [MeSH-major] Chromatography, High Pressure Liquid / methods. Colorectal Neoplasms / urine. Mass Spectrometry / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20617254.001).
  • [ISSN] 1742-2051
  • [Journal-full-title] Molecular bioSystems
  • [ISO-abbreviation] Mol Biosyst
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


58. Uenoyama Y, Seno H, Fukuda A, Sekikawa A, Nanakin A, Sawabu T, Kawada M, Kanda N, Suzuki K, Yada N, Fukui H, Chiba T: Hypoxia induced by benign intestinal epithelial cells is associated with cyclooxygenase-2 expression in stromal cells through AP-1-dependent pathway. Oncogene; 2006 Jun 1;25(23):3277-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia induced by benign intestinal epithelial cells is associated with cyclooxygenase-2 expression in stromal cells through AP-1-dependent pathway.
  • Cyclooxygenase-2 (COX-2) plays important roles in tumor development.
  • Especially in the early-stage colorectal tumors, COX-2 expression is often observed in the tumor stroma.
  • In the present study, we simulated the indirect interaction between epithelial cells and stromal cells in the process of colorectal tumor development using an in vitro co-culture model in which NIH3T3 fibroblasts were co-cultured with 'sparsely' or 'densely' populated intestinal epithelial cells, Intestine-407 as a model of premalignant or benign intestinal epithelial cells, and DLD-1 and Caco-2 as models of malignant epithelial cells.
  • Interestingly, there was pericellular hypoxia in the vicinity of NIH3T3 fibroblasts when co-cultured with 'dense' epithelial cells, and the recovery of the partial pressure of oxygen level resulted in the reduction of enhanced COX-2 expression only in NIH3T3 fibroblasts co-cultured with 'dense' Intestine-407 cells.
  • Thus, pericellular hypoxia of the stromal cells caused by densely populated epithelial cells may be one of the potent COX-2 enhancers before completion of malignant transformation during intestinal tumor development.
  • [MeSH-minor] Animals. Caco-2 Cells. Cell Count. Cell Line, Tumor. Coculture Techniques. Enzyme Induction / physiology. Humans. Mice. NIH 3T3 Cells. Precancerous Conditions / enzymology. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Stromal Cells / enzymology. Stromal Cells / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16407821.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Transcription Factor AP-1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


59. Holdenrieder S, Nagel D, Schalhorn A, Heinemann V, Wilkowski R, von Pawel J, Raith H, Feldmann K, Kremer AE, Müller S, Geiger S, Hamann GF, Seidel D, Stieber P: Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci; 2008 Aug;1137:180-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, the clinical relevance of circulating nucleosomes for diagnosis, staging, prognosis, and therapeutic monitoring of cancer is reviewed.
  • However, because of elevations of nucleosome levels in patients with benign diseases relevant for differential diagnosis, they are not suitable for cancer diagnosis.
  • Concerning tumor staging, nucleosome levels correlate with tumor stage and presence of metastases in gastrointestinal cancer, but not in other tumor types.
  • In addition, therapy outcome is already indicated by the nucleosomal course during the first week of chemo- and radiotherapy in patients with lung, pancreatic, and colorectal cancer as well as in hematologic malignancies.
  • Despite their non-tumor-specificity, kinetics of nucleosomes are valuable markers for the early estimation of therapeutic efficacy and may be helpful to adapting early cancer therapy in the future.
  • [MeSH-major] Macromolecular Substances / blood. Neoplasms / blood. Nucleosomes / metabolism
  • [MeSH-minor] Biomarkers, Tumor / blood. Diagnosis, Differential. Humans. Prognosis

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837945.001).
  • [ISSN] 1749-6632
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Macromolecular Substances; 0 / Nucleosomes
  • [Number-of-references] 68
  •  go-up   go-down


61. Bonin EA, Baron TH: Update on the indications and use of colonic stents. Curr Gastroenterol Rep; 2010 Oct;12(5):374-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Self-expandable metal stent (SEMS) placement is a minimally invasive option for achieving acute colonic decompression in obstructed colorectal cancer.
  • Colorectal stenting offers nonoperative, immediate, and effective colon decompression and allows bowel preparation for an elective oncologic resection.
  • Despite concerns of tumor seeding following endoscopic colorectal stent placement, no difference exists in oncologic long-term survival between patients who undergo stent placement followed by elective resection and those undergoing emergency bowel resection.
  • Colorectal stents have also been used in selected patients with benign colonic strictures.
  • Patients with benign colonic stricture with acute colonic obstruction who are at high risk for emergency surgery can gain temporary relief of obstruction after SEMS placement; the stent can be removed en bloc with the colon specimen at surgery.
  • This article reviews the techniques and indications of SEMS placement for benign and malignant colorectal obstructions.
  • [MeSH-major] Colonoscopy / methods. Colorectal Neoplasms / surgery. Intestinal Obstruction / surgery. Stents / adverse effects
  • [MeSH-minor] Acute Disease. Colon / pathology. Colon / surgery. Colonic Diseases / etiology. Colonic Diseases / surgery. Constriction, Pathologic / surgery. Humans. Palliative Care. Pelvic Neoplasms / complications. Pelvic Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2009 Oct;19(5):e202-5 [19851253.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1096-102 [12190673.001]
  • [Cites] Colorectal Dis. 2009 Feb;11(2):178-83 [18477021.001]
  • [Cites] Lancet. 2006 Nov 4;368(9547):1573-4 [17084754.001]
  • [Cites] Scand J Surg. 2009;98(3):143-7 [19919918.001]
  • [Cites] J Gastrointest Surg. 2009 May;13(5):960-5 [19159986.001]
  • [Cites] South Med J. 2009 Dec;102(12):1257-9 [20016435.001]
  • [Cites] World J Surg. 2009 Jun;33(6):1281-6 [19363580.001]
  • [Cites] Gastrointest Endosc. 2008 Jan;67(1):68-73 [18028916.001]
  • [Cites] J Am Coll Surg. 2001 Jun;192(6):719-25 [11400965.001]
  • [Cites] Brachytherapy. 2009 Jul-Sep;8(3):313-7 [19211311.001]
  • [Cites] Can J Gastroenterol. 2006 Dec;20(12):779-85 [17171197.001]
  • [Cites] Arch Surg. 2009 Dec;144(12):1127-32 [20026830.001]
  • [Cites] Surg Endosc. 2007 Feb;21(2):225-33 [17160651.001]
  • [Cites] Gastrointest Endosc. 2010 Apr;71(4):799-805 [20363422.001]
  • [Cites] Gastrointest Endosc. 2010 Mar;71(3):560-72 [20189515.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] AJR Am J Roentgenol. 2009 Jul;193(1):248-54 [19542421.001]
  • [Cites] Dis Colon Rectum. 2003 Jan;46(1):24-30 [12544518.001]
  • [Cites] World J Gastroenterol. 2007 Aug 7;13(29):3977-80 [17663513.001]
  • [Cites] Curr Oncol Rep. 2009 Jul;11(4):293-7 [19508834.001]
  • [Cites] Curr Opin Gastroenterol. 2009 Jan;25(1):50-4 [19119510.001]
  • [Cites] Scand J Gastroenterol. 2010 Jun;45(6):725-31 [20205505.001]
  • [Cites] Colorectal Dis. 2009 May;11(4):405-9 [18513190.001]
  • [Cites] Radiology. 2010 Mar;254(3):774-82 [20177092.001]
  • [Cites] Dis Colon Rectum. 2009 Sep;52(9):1657-61 [19690497.001]
  • [Cites] Dis Colon Rectum. 2009 Jul;52(7):1272-7 [19571704.001]
  • [Cites] J Am Coll Surg. 2010 Jan;210(1):45-53 [20123331.001]
  • [Cites] BMC Surg. 2007 Jul 03;7:12 [17608947.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3379-84 [19487380.001]
  • [Cites] Am Surg. 2009 Oct;75(10):897-900 [19886130.001]
  • [Cites] Expert Rev Gastroenterol Hepatol. 2008 Jun;2(3):399-409 [19072388.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2009 May;21(5):585-6 [19282771.001]
  • [Cites] Dig Dis Sci. 2010 Jun;55(6):1732-7 [19693667.001]
  • [Cites] Surg Endosc. 2010 Mar;24(3):525-30 [19597776.001]
  • [Cites] Colorectal Dis. 2011 May;13(5):549-54 [20082633.001]
  • [Cites] Dis Colon Rectum. 2010 Feb;53(2):200-12 [20087096.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2007 Apr;17(2):323-39, vi [17556151.001]
  • [Cites] Gastrointest Endosc. 2009 Jun;69(7):1282-7 [19286179.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):2051-7 [15447772.001]
  • [Cites] Gastrointest Endosc. 2009 Mar;69(3 Pt 2):675-80 [19251009.001]
  • [Cites] Surgery. 2008 Nov;144(5):786-92 [19081022.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Nov;7(11):1174-6 [19631290.001]
  • [Cites] Gastrointest Endosc. 2005 Jan;61(1):1-7 [15672048.001]
  • [Cites] Int J Colorectal Dis. 2008 Oct;23(10):1007-12 [18594837.001]
  • [Cites] Gastrointest Endosc. 2006 Dec;64(6):921-4 [17140899.001]
  • [Cites] Am J Gastroenterol. 2010 May;105(5):1087-93 [19935785.001]
  • [Cites] Surg Endosc. 2008 Feb;22(2):454-62 [17704890.001]
  • (PMID = 20703837.001).
  • [ISSN] 1534-312X
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


62. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC Jr, Lokshin AE: Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol; 2010 May 01;28(13):2159-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Ninety-six serum biomarkers were analyzed in sera from healthy women and from patients with ovarian cancer, benign pelvic tumors, and breast, colorectal, and lung cancers, using multiplex xMAP bead-based immunoassays.
  • This panel was selective for ovarian cancer showing SN of 33% for benign pelvic disease, SN of 6% for breast cancer, SN of 0% for colorectal cancer, and SN of 36% for lung cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Immunoassay. Mass Screening / methods. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Algorithms. CA-125 Antigen / blood. Carcinoembryonic Antigen / blood. Data Interpretation, Statistical. Early Detection of Cancer. Epididymal Secretory Proteins / analysis. Female. Humans. Middle Aged. Monte Carlo Method. Neoplasm Staging. Predictive Value of Tests. Prognosis. Reproducibility of Results. Sensitivity and Specificity. Vascular Cell Adhesion Molecule-1 / blood. beta-Defensins

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 May 1;28(13):2128-30 [20368556.001]
  • [Cites] Cancer Chemother Biol Response Modif. 1999;18:418-34 [10800496.001]
  • [Cites] Life Sci. 2001 Jan 12;68(8):861-72 [11213356.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):656-63 [16112717.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):643-50 [11237385.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):194s-199s [12743134.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):355-66 [14764655.001]
  • [Cites] Mol Pathol. 2002 Apr;55(2):110-20 [11950960.001]
  • [Cites] J Cancer Res Clin Oncol. 1989;115(5):456-8 [2808485.001]
  • [Cites] Gynecol Obstet Invest. 1999;48(2):133-7 [10461006.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):129-37 [10067810.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):47-54 [19007974.001]
  • [Cites] Gynecol Oncol. 1988 Jun;30(2):265-73 [3163666.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1035-43 [12637468.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2837-44 [11753957.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4735-7 [9494598.001]
  • [Cites] Clin Biochem. 2003 Mar;36(2):135-43 [12633763.001]
  • [Cites] Dis Markers. 2007;23(5-6):419-31 [18057525.001]
  • [Cites] JAMA. 1995 Dec 27;274(24):1926-30 [8568986.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2190-6 [10786683.001]
  • [Cites] Tumour Biol. 1993;14(2):105-15 [8392219.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 2005 Jun;45(3):211-4 [15904446.001]
  • [Cites] Curr Oncol Rep. 2002 Mar;4(2):165-74 [11822989.001]
  • [Cites] J Endocrinol Invest. 2004 Jun;27(6):528-34 [15717649.001]
  • [Cites] Curr Opin Obstet Gynecol. 2001 Feb;13(1):61-4 [11176234.001]
  • [Cites] Cancer. 1975 May;35(5):1377-81 [47262.001]
  • [Cites] Int J Cancer. 2003 Sep 10;106(4):605-10 [12845660.001]
  • [Cites] Clin Exp Metastasis. 1999 Mar;17(2):131-40 [10411105.001]
  • [Cites] Hum Reprod. 1989 Jan;4(1):1-12 [2651469.001]
  • [Cites] Br J Obstet Gynaecol. 1993 Dec;100(12):1120-4 [8297846.001]
  • [Cites] Gene. 1999 Oct 1;238(2):375-85 [10570965.001]
  • [Cites] Gynecol Oncol. 2007 Oct;107(1):58-65 [17659325.001]
  • [Cites] J Surg Oncol. 1990 Jun;44(2):97-9 [2355747.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):464-75 [16083703.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7 [15824174.001]
  • [Cites] Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10 [10883018.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1880-3 [18708375.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2380-6 [11489816.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):122-4 [7686390.001]
  • [Cites] Acta Obstet Gynecol Scand. 1997 Mar;76(3):283-5 [9093148.001]
  • [Cites] Cancer Lett. 2007 Apr 28;249(1):61-79 [17275179.001]
  • [Cites] Semin Surg Oncol. 1994 Jul-Aug;10(4):242-8 [8091065.001]
  • [Cites] Ann Acad Med Singapore. 1998 Sep;27(5):676-82 [9919339.001]
  • [Cites] Br J Obstet Gynaecol. 1992 Apr;99(4):329-32 [1581280.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1065-72 [18258665.001]
  • [Cites] Br J Cancer. 1994 Dec;70(6):1186-7 [7981074.001]
  • [Cites] Crit Rev Clin Lab Sci. 2004;41(3):265-312 [15307634.001]
  • [Cites] Clin Sci (Lond). 2006 Mar;110(3):279-91 [16464170.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7677-82 [15890779.001]
  • [Cites] Int J Gynecol Cancer. 2001 Jul-Aug;11(4):277-82 [11520365.001]
  • [Cites] Cancer Treat Res. 2002;107:247-58 [11775453.001]
  • [Cites] Gynecol Oncol. 1988 Jan;29(1):66-75 [3422208.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3030-5 [10487660.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2771-4 [12782581.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4059-66 [15381683.001]
  • [Cites] Medscape Womens Health. 1996 Nov;1(11):3 [9746655.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4721-8 [17214332.001]
  • [Cites] Eur J Cancer Prev. 1998 Feb;7(1):23-35 [9511849.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):9-15 [15385104.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1207-10 [10217079.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):103-13 [12582019.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7919-26 [16258091.001]
  • [Cites] Gynecol Oncol. 1997 Jul;66(1):27-30 [9234916.001]
  • [Cites] Cytokine. 2009 Jan;45(1):44-9 [19058974.001]
  • [Cites] Biomed Biochim Acta. 1986;45(3):371-84 [3518711.001]
  • [Cites] Med Oncol. 2008;25(3):279-83 [18071928.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2743-6 [7532929.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Sep;104(9):1024-9 [9307529.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4B):2891-4 [9713482.001]
  • [Cites] Eur J Gynaecol Oncol. 2000;21(2):135-40 [10843471.001]
  • [Cites] Fertil Steril. 2003 Oct;80(4):1068-9; author reply 1069-70 [14556841.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3695-700 [12839961.001]
  • [Cites] Br J Obstet Gynaecol. 1979 Nov;86(11):901-4 [116672.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 3;85(21):1748-51 [8411259.001]
  • [Cites] Hum Reprod. 2005 Jan;20(1):117-21 [15513972.001]
  • [Cites] Tumour Biol. 2002 May-Jun;23(3):185-92 [12218299.001]
  • [Cites] Cancer Invest. 1995;13(2):227-38 [7874576.001]
  • [Cites] Immunol Invest. 2006;35(2):167-79 [16698675.001]
  • [Cites] Eur Cytokine Netw. 2009 Mar;20(1):21-6 [19318317.001]
  • [Cites] Gynecol Oncol. 1998 Jun;69(3):248-52 [9648596.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1B):569-72 [10769727.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5882-90 [15313933.001]
  • [Cites] Int J Oncol. 2005 Feb;26(2):379-84 [15645122.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2005 May 1;120(1):87-90 [15866092.001]
  • [Cites] Biomed Pharmacother. 2004 Jan;58(1):24-38 [14739059.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):297-308 [17569106.001]
  • [Cites] Eur J Clin Chem Clin Biochem. 1994 Mar;32(3):201-7 [8031969.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1641-6 [16985025.001]
  • [Cites] Am Fam Physician. 2003 Sep 15;68(6):1075-82 [14524394.001]
  • (PMID = 20368574.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098642; United States / NCI NIH HHS / CA / CA105009; United Kingdom / Medical Research Council / / G9901012; United States / NCI NIH HHS / CA / R01 CA108990; United Kingdom / Medical Research Council / / G0801228; United States / NCI NIH HHS / CA / U01 CA086381; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / CA086381
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / Vascular Cell Adhesion Molecule-1; 0 / beta-Defensins
  • [Other-IDs] NLM/ PMC2860434
  •  go-up   go-down


63. Sánchez-Fayos Calabuig P, Martín Relloso MJ, Porres Cubero JC: [Genetic profile and molecular bases of pancreatic carcinogenesis]. Gastroenterol Hepatol; 2007 Dec;30(10):592-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The possibility that carcinogenesis is a multiphasic process has been well demonstrated in colorectal cancer, at least in cancers arising from a benign adenomatous polyp.
  • Firstly, d-ADC shows a fairly exclusive genetic-molecular profile, found in 70% of cases; this profile consists of the association of the K-ras oncogene and inactivation of the tumor suppressor genes p16, p53 and DPC4.
  • [MeSH-major] Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18028855.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 51
  •  go-up   go-down


64. Croce MV, Isla-Larrain M, Remes-Lenicov F, Colussi AG, Lacunza E, Kim KC, Gendler SJ, Segal-Eiras A: MUC1 cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue. Histol Histopathol; 2006 08;21(8):849-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC1 cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue.
  • MATERIALS AND METHODS: We studied 163 breast and 89 colorectal cancer specimens, 10 breast and 14 colorectal benign conditions, and 12 breast and 20 colorectal normal samples.
  • From each tumor sample, subcellular fractions were obtained and analyzed by SDS-PAGE and WB.
  • Seven out of ten (70%) benign breast specimens were positive with CT33 while all samples stained with CT2; in normal breast sample tissues, all were positive with both Abs.
  • In colorectal cancer samples, both antibodies stained 47/89 (53%) samples; CT2 reacted in 13/14 (93%) of benign samples while CT33 showed a positive reaction in 9/14 (64%) of benign specimens.
  • By WB, in breast and colorectal cancer samples, similar results were obtained with both antibodies: a main band at about 30kDa which represents the smaller subunit.
  • CONCLUSION: CT33 polyclonal antibody has demonstrated its efficacy to detect MUC1 in breast and colorectal cancer tissues with similar reactivity to CT2.
  • [MeSH-major] Antibodies, Monoclonal / metabolism. Breast Neoplasms / metabolism. Colorectal Neoplasms / metabolism. Mucin-1 / metabolism. Organic Cation Transport Proteins / metabolism
  • [MeSH-minor] Antibodies, Neoplasm / immunology. Antibodies, Neoplasm / metabolism. Biomarkers, Tumor. Breast / anatomy & histology. Breast / metabolism. Breast / pathology. Cell Fractionation. Colon / anatomy & histology. Colon / metabolism. Colon / pathology. Humans. Immunoenzyme Techniques. Rectum / anatomy & histology. Rectum / metabolism. Rectum / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16691537.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; 0 / MUC-1 monoclonal antibody; 0 / Mucin-1; 0 / Organic Cation Transport Proteins; 0 / SLC22A16 protein, human
  •  go-up   go-down


65. Iwai T, Kudo T, Kawamoto R, Kubota T, Togayachi A, Hiruma T, Okada T, Kawamoto T, Morozumi K, Narimatsu H: Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proc Natl Acad Sci U S A; 2005 Mar 22;102(12):4572-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, its expression was markedly down-regulated in gastric and colorectal carcinomas.
  • Tissue specimens from a familial adenomatous polyposis patient showed a clear correlation between the down-regulation of beta3Gn-T6 expression and the degree of dysplasia/neoplasia.
  • These results suggested that the expression of beta3Gn-T6 is closely regulated during differentiation and dedifferentiation. beta3Gn-T6 would be a useful marker for distinguishing between benign adenomas and premalignant lesions.
  • [MeSH-major] Colonic Neoplasms / enzymology. Colonic Neoplasms / genetics. N-Acetylglucosaminyltransferases / genetics. N-Acetylglucosaminyltransferases / physiology
  • [MeSH-minor] Animals. Caco-2 Cells. Cell Line, Tumor. Cell Movement / physiology. Colorectal Neoplasms / enzymology. Colorectal Neoplasms / genetics. Down-Regulation. Humans. Immunohistochemistry. In Vitro Techniques. Lung Neoplasms / enzymology. Lung Neoplasms / genetics. Lung Neoplasms / secondary. Mice. Mice, Inbred BALB C. Stomach Neoplasms / enzymology. Stomach Neoplasms / genetics. Transfection

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10231-3 [12149519.001]
  • [Cites] J Biol Chem. 2002 Jun 21;277(25):22623-38 [11925450.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):573-84 [12407114.001]
  • [Cites] Anal Biochem. 1976 Aug;74(2):466-76 [962103.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2051-5 [6952252.001]
  • [Cites] J Natl Cancer Inst. 1983 Aug;71(2):231-51 [6576183.001]
  • [Cites] Cancer Res. 1985 Jun;45(6):2405-14 [3886132.001]
  • [Cites] J Biol Chem. 1985 Jul 15;260(14):8262-71 [4008490.001]
  • [Cites] Biochemistry. 1985 Apr 9;24(8):1866-74 [3160388.001]
  • [Cites] J Natl Cancer Inst. 1985 Sep;75(3):447-54 [2863413.001]
  • [Cites] J Biol Chem. 1985 Dec 15;260(29):15510-5 [4066681.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):67-95 [10580130.001]
  • [Cites] J Soc Biol. 1999;193(1):85-99 [10851560.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Jan;280(1):L181-7 [11133508.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 May;280(5):G1043-8 [11292614.001]
  • [Cites] Biochem J. 2001 Sep 15;358(Pt 3):657-64 [11577689.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):178-86 [11677243.001]
  • [Cites] Cancer Res. 1986 May;46(5):2627-32 [3516383.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4841-7 [3731131.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3239-45 [2438036.001]
  • [Cites] Nature. 1987 Aug 13-19;328(6131):614-6 [3039373.001]
  • [Cites] Cancer Res. 1988 Jul 1;48(13):3834-42 [3288336.001]
  • [Cites] J Biol Chem. 1988 Oct 15;263(29):15146-50 [2971663.001]
  • [Cites] Cancer Res. 1989 Feb 1;49(3):745-52 [2910493.001]
  • [Cites] J Biol Chem. 1991 Jan 25;266(3):1772-82 [1824844.001]
  • [Cites] Genomics. 1991 Oct;11(2):247-51 [1663069.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1199-211 [1312973.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1993 Jun;48(6):423-8 [8341719.001]
  • [Cites] Eur J Biochem. 1994 Jun 1;222(2):415-24 [8020479.001]
  • [Cites] Glycobiology. 1994 Dec;4(6):873-84 [7734850.001]
  • [Cites] Glycobiology. 1995 May;5(3):351-7 [7655172.001]
  • [Cites] Eur J Biochem. 1995 Oct 15;233(2):607-17 [7588808.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2237-44 [8625291.001]
  • [Cites] Gastroenterology. 1996 May;110(5):1354-67 [8613039.001]
  • [Cites] Cell Biol Int. 1997 May;21(5):281-7 [9243803.001]
  • [Cites] Biochemistry. 1998 Apr 7;37(14):4916-27 [9538010.001]
  • [Cites] Keio J Med. 1998 Mar;47(1):10-8 [9560527.001]
  • [Cites] Clin Exp Metastasis. 1998 Apr;16(3):267-74 [9568644.001]
  • [Cites] Biochemistry. 1999 May 25;38(21):6817-25 [10346903.001]
  • [Cites] J Biol Chem. 1999 Jul 23;274(30):21209-16 [10409676.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4083-9 [10463611.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):12802-9 [11821425.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47724-31 [12361956.001]
  • (PMID = 15755813.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.4.1.- / N-Acetylglucosaminyltransferases; EC 2.4.1.- / UDP-GlcNAc GalNAc-peptide beta1,3-N-acetylglucosaminyltransferase
  • [Other-IDs] NLM/ PMC555466
  •  go-up   go-down


66. Shen C, Hu L, Xia L, Li Y: Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients. Jpn J Clin Oncol; 2008 Nov;38(11):770-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients.
  • OBJECTIVE: To establish a sensitive method for the early detection of circulating tumor cells (CTCs) in peripheral blood (PB) of colorectal cancer (CRC) patients.
  • METHODS: PB samples were collected from 156 CRC patients, 40 benign colorectal disease patients, 40 healthy individuals and 45 patients with other solid tumors.
  • The expression of the three mRNAs in CRC patients was significantly higher than that in benign control and healthy volunteers, and the expression of survivin and CK20 was not significantly higher than that of patients with other solid tumors.
  • However, the expression of CEA mRNA was significantly higher than that of patients with other solid tumors.
  • [MeSH-major] Carcinoembryonic Antigen / blood. Colorectal Neoplasms / blood. Colorectal Neoplasms / diagnosis. Microtubule-Associated Proteins / blood. Neoplasm Proteins / blood. Neoplastic Cells, Circulating / chemistry. RNA, Messenger / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. Cell Line, Tumor. Female. Humans. Inhibitor of Apoptosis Proteins. Keratin-20 / blood. Keratin-20 / genetics. Leukocytes, Mononuclear / chemistry. Leukocytes, Mononuclear / cytology. Male. Middle Aged. Molecular Sequence Data. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18845519.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Carcinoembryonic Antigen; 0 / Inhibitor of Apoptosis Proteins; 0 / KRT20 protein, human; 0 / Keratin-20; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


67. Garneau H, Paquin MC, Carrier JC, Rivard N: E2F4 expression is required for cell cycle progression of normal intestinal crypt cells and colorectal cancer cells. J Cell Physiol; 2009 Nov;221(2):350-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E2F4 expression is required for cell cycle progression of normal intestinal crypt cells and colorectal cancer cells.
  • Immunofluorescence experiments in human fetal intestine revealed that cells expressing high nuclear levels of E2F4 also expressed cyclin A protein.
  • Lastly, E2F4 and its target cyclin A were up-regulated and mostly nuclear in human colorectal tumor cells in comparison to the corresponding benign epithelium.
  • These results indicate that nuclear E2F4 may be determinant in the promotion of proliferation of human intestinal epithelial crypt cells and colorectal cancer cells.
  • [MeSH-major] Cell Cycle. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. E2F4 Transcription Factor / metabolism. Intestines / cytology. Intestines / metabolism
  • [MeSH-minor] Agar. Cell Line, Tumor. Cell Nucleus / metabolism. Cell Proliferation. Cyclin A / metabolism. DNA / biosynthesis. Down-Regulation. Epithelial Cells / cytology. Epithelial Cells / metabolism. G1 Phase. Gene Expression Regulation, Neoplastic. Gene Knockdown Techniques. Humans. Protein Transport. S Phase

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AGAR-AGAR .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562678.001).
  • [ISSN] 1097-4652
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin A; 0 / E2F4 Transcription Factor; 0 / E2F4 protein, human; 9002-18-0 / Agar; 9007-49-2 / DNA
  •  go-up   go-down


68. Gabra HO, Jesudason EC, McDowell HP, Pizer BL, Losty PD: Sacrococcygeal teratoma--a 25-year experience in a UK regional center. J Pediatr Surg; 2006 Sep;41(9):1513-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Surgical and tumor registries identified patients with SCT between 1977 and 2001.
  • Surgery comprised tumor excision with coccygectomy.
  • Histology was benign in 26 (79%), malignant in 6 (18%), and immature in a single patient.
  • Neuropathic bladder or bowel disturbance was identified in 7 of 20 patients on long-term follow-up.
  • CONCLUSIONS: Antenatal diagnosis of SCT appears to be increasing.
  • Parental counseling should include the continence problems that may follow removal of even benign tumors.
  • Resection by surgical oncologists and reconstruction by colorectal specialists may improve function.
  • [MeSH-major] Soft Tissue Neoplasms / diagnosis. Teratoma / diagnosis

  • Genetic Alliance. consumer health - Sacrococcygeal Teratoma.
  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16952583.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0802057
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Gold DV, Stein R, Burton J, Goldenberg DM: Enhanced expression of CD74 in gastrointestinal cancers and benign tissues. Int J Clin Exp Pathol; 2010;4(1):1-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced expression of CD74 in gastrointestinal cancers and benign tissues.
  • Colorectal and gastric carcinomas gave similar results with 60% and 86%, respectively, positive for CD74 with an intense, diffuse staining pattern.
  • These findings are supportive of a role for CD74 in the development and maintenance of gastrointestinal neo-plasia, and provide a rationale for development of therapeutic agents that are able to block CD74 function, specifically within the tumor cell.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Antigens, Differentiation, B-Lymphocyte / metabolism. Digestive System Neoplasms / metabolism. Histocompatibility Antigens Class II / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Humans. Immunohistochemistry. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Tissue Array Analysis

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2001 May;158(5):1639-51 [11337362.001]
  • [Cites] J Histochem Cytochem. 2005 Dec;53(12):1481-9 [15923369.001]
  • [Cites] Cancer Lett. 2001 Jul 10;168(1):87-91 [11368882.001]
  • [Cites] Scand J Immunol. 2001 Jul-Aug;54(1-2):39-44 [11439146.001]
  • [Cites] J Exp Med. 2003 Jun 2;197(11):1467-76 [12782713.001]
  • [Cites] Gene Ther. 2003 Aug;10(17):1512-8 [12900767.001]
  • [Cites] Cancer Immunol Immunother. 2003 Oct;52(10):592-8 [12827305.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5546-50 [15313888.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6606-11 [15475450.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Dec;80(24):7395-9 [6324166.001]
  • [Cites] Cancer Res. 1989 Aug 15;49(16):4568-77 [2663143.001]
  • [Cites] Nature. 1990 Jun 14;345(6276):615-8 [2190094.001]
  • [Cites] J Immunol. 1992 Oct 1;149(7):2391-6 [1527384.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2419-26 [16638847.001]
  • [Cites] J Immunol. 2006 Jun 1;176(11):6794-801 [16709839.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4807-16 [16484589.001]
  • [Cites] Immunity. 2006 Oct;25(4):595-606 [17045821.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5556s-5563s [17875789.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7380-7 [18094420.001]
  • [Cites] J Biol Chem. 2008 Feb 1;283(5):2784-92 [18056708.001]
  • [Cites] Infect Immun. 2008 Jul;76(7):3233-40 [18474653.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2808-17 [19351768.001]
  • [Cites] Eur J Cancer. 2009 Jun;45(9):1654-63 [19269807.001]
  • [Cites] World J Gastroenterol. 2009 Jun 21;15(23):2855-61 [19533806.001]
  • [Cites] World J Gastroenterol. 2010 Jul 14;16(26):3258-66 [20614481.001]
  • [Cites] J Neurooncol. 2010 Nov;100(2):177-86 [20443131.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8581-5 [8397411.001]
  • [Cites] Nature. 1994 Apr 7;368(6471):551-4 [8139689.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):64-71 [8540610.001]
  • [Cites] Biochem J. 1996 Nov 15;320 ( Pt 1):293-300 [8947500.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6886-91 [9192661.001]
  • [Cites] Virchows Arch. 1999 Jul;435(1):32-6 [10431843.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3705-11 [15297317.001]
  • [Cites] Cancer Biol Ther. 2004 Dec;3(12):1254-61 [15477757.001]
  • [Cites] J Immunol. 2005 Jul 1;175(1):171-6 [15972644.001]
  • [Cites] Immunology. 1999 Oct;98(2):296-302 [10540230.001]
  • (PMID = 21228923.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096924
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Biomarkers, Tumor; 0 / Histocompatibility Antigens Class II; 0 / invariant chain
  • [Other-IDs] NLM/ PMC3016099
  • [Keywords] NOTNLM ; CD74 / colon carcinoma / gastric carcinoma / invariant chain / pancreatic carcinoma
  •  go-up   go-down


70. Zheng GX, Wang CX, Qu X, Deng XM, Deng BP, Zhang J: Establishment of serum protein pattern for screening colorectal cancer using SELDI-TOF-MS. Exp Oncol; 2006 Dec;28(4):282-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of serum protein pattern for screening colorectal cancer using SELDI-TOF-MS.
  • AIM: The purpose of this study is to develop a proteomic pattern for distinguishing individuals with colorectal cancer from healthy controls and monitoring micrometastasis using SELDI-TOF-MS.
  • METHODS: A training set consisting of 63 patients with colorectal cancer, 20 patients with benign colorectal diseases and 26 healthy volunteers was used to develop a proteomic model that discriminated colorectal cancer effectively.
  • This model was validated in the test set with sensitivity of 87.5% and specificity of 93.8% which was significantly better than the combination use of CEA, CA199 and CA242 (sensitivity 62.4%) for early detection of colorectal cancer.
  • We also detected two proteins (m/z: 9184.4 and 9340.9) that can discriminate patients with primary colorectal cancer from metastatic colorectal cancer.
  • CONCLUSIONS: The four-peak model and two peaks (m/z: 2753.8 and 4172.4) detected in this study have the potential for assistance in diagnostics and therapeutic strategies in colorectal cancer and the two proteins (m/z: 9184.4 and 9340.9) were effective biomarkers for monitoring micrometastasis.
  • [MeSH-major] Biomarkers, Tumor / blood. Colorectal Neoplasms / blood. Colorectal Neoplasms / diagnosis. Mass Screening / methods. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17285111.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteins
  •  go-up   go-down


71. Hall PA, Todd CB, Hyland PL, McDade SS, Grabsch H, Dattani M, Hillan KJ, Russell SE: The septin-binding protein anillin is overexpressed in diverse human tumors. Clin Cancer Res; 2005 Oct 1;11(19 Pt 1):6780-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The septin-binding protein anillin is overexpressed in diverse human tumors.
  • The median level of anillin mRNA expression was higher in tumors than normal tissues (median fold increase 2.58; 95% confidence intervals, 2.19-5.68, P < 0.0001) except in the central nervous system where anillin mRNA levels were lower in tumors.
  • Anillin mRNA expression was analyzed during tumor progression in breast, ovarian, kidney, colorectal, hepatic, lung, endometrial, and pancreatic tumors and in all tissues there was progressive increase in anillin mRNA expression from normal to benign to malignant to metastatic disease.
  • Thus, anillin is overexpressed in diverse common human tumors, but not simply as a consequence of being a proliferation marker.
  • [MeSH-major] Contractile Proteins / chemistry. Contractile Proteins / physiology. Cytoskeletal Proteins / metabolism. Gene Expression Regulation, Neoplastic. Neoplasms / metabolism
  • [MeSH-minor] Actins / metabolism. Biomarkers, Tumor. Blotting, Northern. Cell Cycle Proteins / metabolism. Cell Line, Tumor. Cell Nucleus / metabolism. Central Nervous System / embryology. Cloning, Molecular. DNA, Complementary / metabolism. Exons. HeLa Cells. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Microfilament Proteins / metabolism. Mitochondrial Proteins / metabolism. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction. Protein Binding. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tissue Distribution. Transcription, Genetic

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203764.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Contractile Proteins; 0 / Cytoskeletal Proteins; 0 / DNA, Complementary; 0 / Ki-67 Antigen; 0 / Microfilament Proteins; 0 / Mitochondrial Proteins; 0 / RNA, Messenger; 0 / anillin
  •  go-up   go-down


72. He Q, Zhang P, Zou L, Li H, Wang X, Zhou S, Fornander T, Skog S: Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep; 2005 Oct;14(4):1013-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity.
  • Activity of thymidine kinase 1 in serum (STK) is a useful marker for leukaemia and lymphoma, but not for solid tumors.
  • We investigate thymidine kinase 1 concentration in serum (S-TK1) as a potential tumor marker.
  • S-TK1 concentration and STK activity levels were determined in 9 human malignant diseases (breast, gastric, rectal, colorectal, lung, brain cancer, hepatoma, lymphoma, leukaemia) and in benign and non-cancerous diseases, representing 850 preoperative cases.
  • S-TK1 concentrations and STK activity levels in preoperative malignant patients were significantly higher than in healthy individuals, in patients with benign tumors and in those with non-cancerous diseases.
  • Significant correlations between concentration and activity level were only found in healthy individuals, in patients with benign tumors, and in some patients with malignancies, i.e. leukaemia, and breast and gastric cancers.
  • We conclude that S-TK1 concentration is a more sensitive tumor marker in solid malignancies than is STK activity.
  • [MeSH-major] Biomarkers, Tumor. Neoplasms / blood. Neoplasms / diagnosis. Thymidine Kinase / blood
  • [MeSH-minor] Breast Neoplasms / pathology. Cell Line, Tumor. Cell Proliferation. Dose-Response Relationship, Drug. Female. Humans. Male. Neoplasm Staging. Radioimmunoassay / methods. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142366.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.21 / Thymidine Kinase; EC 2.7.1.21 / thymidine kinase 1
  •  go-up   go-down


73. Robles R, Abellán B, Marín C, Fernández JA, Ramírez P, Morales D, Ramírez M, Sánchez F, Parrilla P: [Laparoscopic resection of solid liver tumors. Presentation of our experience]. Cir Esp; 2005 Oct;78(4):238-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic resection of solid liver tumors. Presentation of our experience].
  • INTRODUCTION: Laparoscopic liver resection (LLR) of solid liver tumors (SLT) has not become widespread due to technical problems, the risk of air embolism, and possible tumoral spread in malignant lesions.
  • Preoperative diagnosis was liver metastases from colorectal carcinoma in 11 patients and benign tumor in the remaining five patients.
  • VII) and two local resections of benign tumors.
  • CONCLUSION: LLR of benign SLTs shows all the advantages of laparoscopy.
  • [MeSH-major] Hepatectomy / methods. Laparoscopy. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16420832.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


74. Czeczot H, Scibior-Bentkowska D, Skrzycki M, Majewska M, Podsiad M: [Lipid peroxidation level in gastrointestinal tract tumors]. Pol Merkur Lekarski; 2010 Nov;29(173):309-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lipid peroxidation level in gastrointestinal tract tumors].
  • Oxygen free radicals and their reactive derivatives participate in formation of chronic inflammation states, which facilitate development of gastrointestinal tract tumors.
  • The aim of the study was the determination of lipid peroxidation level in gastrointestinal tract tumors (stomach, liver, colon, and colorectal cancer to liver metastases).
  • MATERIAL AND METHODS: Materials for studies were obtained from 150 patients with gastrointestinal tract tumors: 10 with stomach cancer, 30 with malignant and benign liver cancers, 60 with primary colorectal cancer, and 50 with metachronous colorectal cancer liver metastases.
  • Tumor specimens, and normal adjacent tissues (6-7 cm from the edge of the tumor), which served as control tissue in studies, were collected from patients (with their consent) during surgery.
  • RESULTS: The study showed the highest concentration of TBARS in benign, and the lowest in malignant liver tumors.
  • Other types of gastrointestinal tumors studied, were characterized by similar levels of lipid peroxidation.
  • TBARS concentration in these tumors was approximately 2-fold higher than in malignant liver tumors and much lower than in benign tumors.
  • In all cancers of the digestive tract with the exception of malignant liver tumors increased level of TBARS was found, comparing with control tissue.
  • The level of lipid peroxidation in liver cirrhosis and malignant liver tumors was similar.
  • There were no significant differences in TBARS concentration in the tumors of particular sections of the intestine and normal colon.
  • The highest concentration of TBARS was found in G1 grade of colorectal cancer.
  • The highest level of lipid peroxidation, expressed as the concentration of TBARS was found in the I stage of colorectal cancer clinical advancement.
  • The changes of lipid peroxidation level--a marker of oxidative stress in gastrointestinal tumors appear to be closely associated with their development stages (liver cirrhosis/malignant liver cancer; colorectal cancer/colorectal cancer liver metastases) and are likely to create such conditions, in which cancerous cells may proliferate, undergo gradual dedifferentiation and malignancy, and generate metastases.
  • [MeSH-major] Gastrointestinal Neoplasms / metabolism. Lipid Peroxidation. Liver Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21268915.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


75. Chiang JM, Lin YS: Tumor spectrum of adult intussusception. J Surg Oncol; 2008 Nov 1;98(6):444-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor spectrum of adult intussusception.
  • Most general and colorectal surgeons are unfamiliar with its etiology and optimal management.
  • Data related to presentation, diagnosis, treatment, and pathology were analyzed.
  • Neoplasm was identified as the cause of intussusception in 66 (92%) cases, and 6 (8%) were idiopathic.
  • Lipoma (15 of 40 patients, 38%) and Peutz-Jegher adenoma (10 of 40 patients, 25%) were the two most common lesions of benign small bowel neoplasms while 27% (3 of 11) of malignant enteric intussusception cases were malignant lymphoma and metastatic respectively.
  • CONCLUSION: Lipoma is the most common benign tumor in both small and large bowel intussusception.
  • Whereas 80% of tumors associated with small bowel intussusception were benign, two-thirds of colonic intussusceptions had resulted from primary adenocarcinoma.
  • [MeSH-major] Intestinal Diseases / etiology. Intestinal Neoplasms / complications. Intussusception / etiology
  • [MeSH-minor] Abdominal Pain / etiology. Adenocarcinoma / complications. Adenoma / complications. Adolescent. Adult. Aged. Aged, 80 and over. Cystadenocarcinoma, Mucinous / complications. Female. Humans. Lipoma / complications. Lymphoma, Large B-Cell, Diffuse / complications. Male. Middle Aged. Peutz-Jeghers Syndrome / complications. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [ErratumIn] J Surg Oncol. 2009 Jun 1;99(7):457
  • (PMID = 18668640.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


76. Wheless SA, McKinney KA, Zanation AM: A prospective study of the clinical impact of a multidisciplinary head and neck tumor board. Otolaryngol Head Neck Surg; 2010 Nov;143(5):650-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of the clinical impact of a multidisciplinary head and neck tumor board.
  • OBJECTIVE: There have been no studies undertaken on the effect of the multidisciplinary head and neck tumor board on treatment planning.
  • The objective of this study was to determine the efficacy of the multidisciplinary tumor board in altering diagnosis, stage, and treatment plan in patients with head and neck tumors.
  • SUBJECTS AND METHODS: A prospective study of the discussions concerning 120 consecutive patients presented at a multidisciplinary head and neck tumor board was performed.
  • As each patient was presented, a record was made of the "pre-conference" diagnosis, stage, and treatment plan.
  • After case discussion, the "post-conference" diagnosis, stage, and treatment plan were recorded.
  • Results are compared between malignant and benign tumor cohorts.
  • RESULTS: The study population comprised 120 patients with new presentations of head and neck tumors: 84 malignancies and 36 benign tumors.
  • Approximately 27 percent of patients had some change in tumor diagnosis, stage, or treatment plan.
  • Change in treatment was significantly more common in cases of malignancy, occurring in 24 percent of patients versus six percent of benign tumors (P = 0.0199).
  • CONCLUSION: A multidisciplinary tumor board affects diagnostic and treatment decisions in a significant number of patients with newly diagnosed head and neck tumors.
  • The multidisciplinary approach to patient care may be particularly effective in managing malignant tumors, in which treatment plans are most frequently altered.
  • [MeSH-major] Decision Making. Head and Neck Neoplasms / diagnosis. Interdisciplinary Communication. Medical Audit / organization & administration. Medical Oncology / methods. Otolaryngology / methods. Radiation Oncology / methods

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Academy of Otolaryngology–Head and Neck Surgery Foundation. Published by Mosby, Inc. All rights reserved.
  • [Cites] Curr Oncol Rep. 2003 Mar;5(2):147-51 [12583832.001]
  • [Cites] Curr Opin Oncol. 2004 May;16(3):220-4 [15069316.001]
  • [Cites] Urol Oncol. 2011 Jul-Aug;29(4):378-82 [19576797.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2009 Sep;21(7):525-31 [19535232.001]
  • [Cites] Oncology. 2008;75(3-4):186-91 [18841033.001]
  • [Cites] Ann Oncol. 2008 Sep;19 Suppl 7:vii195-9 [18790948.001]
  • [Cites] J Support Oncol. 2008 Mar;6(3):125-31 [18402304.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2008 Apr;16(2):103-7 [18327027.001]
  • [Cites] Colorectal Dis. 2008 Jan;10(1):63-8 [18078461.001]
  • [Cites] Int J Oral Surg. 1978 Aug;7(4):291-5 [100441.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 Jul;121(1):113-8 [10388890.001]
  • [Cites] J Telemed Telecare. 2005;11(4):205-10 [16007751.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Lancet Oncol. 2006 Nov;7(11):951-4 [17081921.001]
  • [Cites] Eur J Cancer. 2007 Apr;43(6):1002-10 [17329094.001]
  • [Cites] J Thorac Oncol. 2007 Jan;2(1):69-72 [17410013.001]
  • (PMID = 20974334.001).
  • [ISSN] 1097-6817
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Grant] United States / NIDCD NIH HHS / DC / T32 DC005360; United States / NIDCD NIH HHS / DC / T32 DC005360
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS248576; NLM/ PMC2994101
  •  go-up   go-down


77. Céspedes MV, Sancho FJ, Guerrero S, Parreño M, Casanova I, Pavón MA, Marcuello E, Trias M, Cascante M, Capellà G, Mangues R: K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12. Carcinogenesis; 2006 Nov;27(11):2190-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Different mutant amino acids in the Ras proteins lead to distinct transforming capacities and different aggressiveness in human tumors.
  • K-Ras Asp12 (K12D) is more prevalent in benign than in malignant human colorectal tumors, whereas K-Ras Val12 (K12V) associates with more advanced and metastatic carcinomas, higher recurrence and decreased survival.
  • We studied tumor histology and growth, apoptotic and mitotic rates, activation of signal transduction pathways downstream of Ras and regulation of the cell cycle and apoptotic proteins in tumors derived from the implanted transformants.
  • We found that the K12V oncogene induces a more aggressive tumorigenic phenotype than the K12D oncogene, whereas K12C does not induce tumors in this model.
  • Thus, K12V mutant tumors proliferate about seven times faster, and have higher cellularity and mitotic rates than the K12D mutant tumors.
  • A molecular analysis of the induced tumors shows that the K12V mutant protein interacts with Raf-1 and transduces signals mainly through the Erk pathway.
  • Unexpectedly, in tumors induced by the K12D oncogene, the K-Ras mutant protein does not interact with Raf-1 nor activates the Erk canonical pathway.
  • Finally, the higher growth rate of the K12V tumors associates with enhanced Rb phosphorylation, and PCNA and cyclin B upregulation, consistent with faster G1/S and G2/M transitions, without alteration of apoptotic regulation.
  • [MeSH-minor] Animals. Apoptosis. Male. Mice. Mice, Nude. NIH 3T3 Cells. Neoplasm Metastasis. Protein Binding. Signal Transduction


78. Gottwald L, Korczyński J, Góra E, Bieńkiewicz A: [Adnexal tumors after surgical treatment of colorectal cancer]. Ginekol Pol; 2008 Apr;79(4):259-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adnexal tumors after surgical treatment of colorectal cancer].
  • OBJECTIVE: The risk of metastatic ovarian tumor is significantly higher in case of women with a history of colorectal cancer.
  • DESIGN: The purpose of the study was to evaluate the clinical presentation and histopathology of adnexal tumors in case of female patients with a history of colorectal adenocarcinoma.
  • MATERIAL AND METHODS: A retrospective study on 13 women (each with a history of colorectal carcinoma, operated due to adnexal tumor between 2004 and 2007), has been conducted.
  • Subject characteristics, ultrasound, CT, serum tumor markers levels, histopathology and findings at surgery were analyzed.
  • RESULTS: Time distance between colorectal cancer surgery and ovarian tumor operation - measured in months -was shorter in cases of malignant neoplasms (10.13 +/- 3.98) than in benign tumors (26.2 +/- 19.37).
  • Ultrasound examination showed solid-cystic adnexal tumors in 8 malignant cases, and ovarian cysts in 5 benign conditions.
  • Unilateral adnexectomy only took place in one case of benign tumor and in one case of disseminated neoplasmatic disease.
  • CONCLUSIONS: When evaluating a patient with an adnexal tumor, a history of malignancy strongly suggests a metastatic nature.
  • The use of ultrasound associated with plasma levels of Ca 125, Ca 19-9 and CEA, represents a useful method of preoperative assessment of ovarian tumors.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. CA-125 Antigen / blood. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Female. Humans. Middle Aged. Neoplasm Staging. Poland. Retrospective Studies. Risk Assessment. Ultrasonography, Doppler, Color / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18592863.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


79. Ben QW, Zhao Z, Ge SF, Zhou J, Yuan F, Yuan YZ: Circulating levels of periostin may help identify patients with more aggressive colorectal cancer. Int J Oncol; 2009 Mar;34(3):821-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating levels of periostin may help identify patients with more aggressive colorectal cancer.
  • Elevated levels of periostin have been implicated as playing important roles in tumor invasion and metastasis in various tissues.
  • Thus, we determined whether serum periostin levels were associated with progression and poor prognosis in colorectal cancer (CRC) patients.
  • The serum levels of periostin in CRC patients (40.9+/-15.4 ng/ml) were significantly elevated compared to that in healthy volunteers (21.0+/-7.3 ng/ml, P<0.0001) and benign colorectal polyps or adenomas (22.4+/-8.5 ng/ml, P<0.0001).
  • Periostin may be produced by the stromal cells surrounding the tumor, but not by the CRC cells themselves.
  • [MeSH-major] Biomarkers, Tumor / blood. Cell Adhesion Molecules / blood. Colorectal Neoplasms / blood. Colorectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Male. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212687.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / POSTN protein, human; 0 / RNA, Messenger
  •  go-up   go-down


80. Wong SC, Chan CM, Ma BB, Hui EP, Ng SS, Lai PB, Cheung MT, Lo ES, Chan AK, Lam MY, Au TC, Chan AT: Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. Clin Cancer Res; 2009 Feb 1;15(3):1005-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients.
  • PURPOSE: Current immunomagnetic enrichment method can only detect general epithelial antigens of circulating tumor cells (CTC).
  • Further characterization of the CTCs to provide specific information on the tumor type is not possible.
  • We attempted to overcome this drawback by developing the methodology for using a gastrointestinal-specific anti-cytokeratin (CK) 20 antibody to detect CTCs in colorectal cancer patients' blood.
  • EXPERIMENTAL DESIGN: The protocol was validated using a colorectal cancer SW480 cell line.
  • The clinical significance of findings in colorectal cancer was investigated by detecting CK20-positive CTCs (pCTC) in patients with colorectal cancer, other common cancers, colorectal adenoma, benign colorectal diseases, and normal subjects.
  • Moreover, the malignant nature of CK20 pCTCs was examined by comparing chromosome 17 aberration patterns with those from the corresponding primary tumors.
  • When applied in patient samples, the detection rates were 62% (132 colorectal cancer patients; median number = 11 CTCs), 0% (120 patients with other common cancers), 6% (50 colorectal adenoma patients), 0% (120 patients with benign colorectal diseases), and 0% (40 normal subjects).
  • Furthermore, statistical analysis showed that CK20 pCTC numbers were associated with tumor-node-metastasis stage and lymph node status.
  • Using the median CK20 pCTC numbers as the cutoff points, stratified groups of colorectal cancer patients had significant differences in their recurrence, metastasis, and survival.
  • Finally, chromosome 17 aneusomy in 90% of colorectal cancer patients with CK20 pCTCs matched with those from the primary tumors.
  • CONCLUSIONS: Detection of CK20 pCTCs using the new protocol could generate clinically important information for colorectal cancer patients.
  • [MeSH-major] Colorectal Neoplasms / blood. Immunomagnetic Separation / methods. Keratin-20 / blood. Neoplastic Cells, Circulating / chemistry
  • [MeSH-minor] Adenoma / blood. Biomarkers, Tumor / blood. Cell Line, Tumor. Chromosomes, Human, Pair 17. Humans. Prognosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188172.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20
  •  go-up   go-down


81. Xi L, Gooding W, McCarty K, Godfrey TE, Hughes SJ: Identification of mRNA markers for molecular staging of lymph nodes in colorectal cancer. Clin Chem; 2006 Mar;52(3):520-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of mRNA markers for molecular staging of lymph nodes in colorectal cancer.
  • Surprisingly, no systematic analysis of potential mRNA markers for colorectal cancer has been reported.
  • We therefore performed an extensive mRNA marker survey for colorectal cancers.
  • We analyzed all markers by quantitative reverse transcription-PCR on a limited set of primary tumors and benign lymph nodes.
  • CONCLUSIONS: Several mRNA markers are capable of providing exceptionally accurate characterization of lymph node status in colorectal cancer.
  • An automated, multimarker, quantitative reverse transcription-PCR assay for characterization of lymph nodes from colorectal cancer patients may be useful for improved staging and therapeutic decision making in colorectal cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colorectal Neoplasms / diagnosis. Lymph Nodes / pathology. RNA, Messenger / analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16510433.001).
  • [ISSN] 0009-9147
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-01958
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


82. Zhang JF, Gao CF, Wang XL, Zheng GB, Li DH: [Screening and expression of tumor markers in colorectal carcinoma]. Zhonghua Wai Ke Za Zhi; 2007 Apr 1;45(7):459-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Screening and expression of tumor markers in colorectal carcinoma].
  • OBJECTIVE: To screen the tumor markers of colorectal carcinoma and to investigate their expression in preoperative and postoperative serum.
  • METHODS: The distinct proteins in serum were detected in 87 cases of colorectal carcinoma, 68 cases of benign colorectal diseases and 56 healthy people by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS).
  • The distinct proteins in serum were detected in 87 cases of colorectal carcinoma pre-operation and within 15 days post operation with the same methods.
  • Compared with benign colorectal diseases and healthy control, the expression of the two proteins was obviously up-regulated in colorectal carcinoma (P < 0.01).
  • Compared with pre-operation, the expression on the 1(st) day post operation was obviously up-regulated (P < 0.01), and the expression decreased to pre-operative level on the 4(th) day post operation.
  • CONCLUSIONS: Two proteins with mass-to-charge ratios of 5955 Da and 5972 Da could be regarded as tumor markers in colorectal carcinoma, the expression may has some regularity.
  • [MeSH-major] Biomarkers, Tumor / blood. Colorectal Neoplasms / blood. Mass Screening / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17686301.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


83. Chuang D, Paddison JS, Booth RJ, Hill AG: Differential production of cytokines following colorectal surgery. ANZ J Surg; 2006 Sep;76(9):821-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential production of cytokines following colorectal surgery.
  • BACKGROUND: Colorectal surgery is associated with a number of postoperative complications, including anastomotic leak and local recurrence.
  • Cytokines are secreted into the peritoneal cavity after colorectal surgery and have a number of metabolic and immunological effects.
  • METHODS: Patients undergoing either elective rectal excision or colectomy for benign or malignant disease were recruited into the study.
  • The drain fluid was assayed for interleukin (IL)-1beta, tumour necrosis factor-alpha, IL-6, IL-8, IL-10 and IL-13 using multiplexed biomarker immunoassays.
  • [MeSH-major] Colon / secretion. Colon / surgery. Interleukins / secretion. Rectum / secretion. Rectum / surgery. Tumor Necrosis Factor-alpha / secretion

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16922906.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Interleukins; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


84. Garcia-Donas J, Rodriguez N, Jara C, Urioste M, Nevado M, Cañamero M, Cuartero V, Albillos J, Vega D, Quintans A: Retrorectal cystic hamartoma as benign cause of CA 19-9 elevation. J Clin Oncol; 2007 Sep 1;25(25):4012-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrorectal cystic hamartoma as benign cause of CA 19-9 elevation.
  • [MeSH-major] Biomarkers, Tumor / metabolism. CA-19-9 Antigen / metabolism. Hamartoma / diagnosis. Hamartoma / metabolism. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / metabolism
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / analysis. Adult. Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Diagnosis, Differential. Female. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / metabolism. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / metabolism. Nuclear Proteins / analysis. Rectal Neoplasms / diagnosis. Sacrococcygeal Region

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17761987.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / MLH1 protein, human; 0 / Nuclear Proteins
  •  go-up   go-down


85. Lind GE, Ahlquist T, Kolberg M, Berg M, Eknaes M, Alonso MA, Kallioniemi A, Meling GI, Skotheim RI, Rognum TO, Thiis-Evensen E, Lothe RA: Hypermethylated MAL gene - a silent marker of early colon tumorigenesis. J Transl Med; 2008;6:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Tumor-derived aberrantly methylated DNA might serve as diagnostic biomarkers for cancer, but so far, few such markers have been identified.
  • The aim of the present study was to investigate the potential of the MAL (T-cell differentiation protein) gene as an early epigenetic diagnostic marker for colorectal tumors.
  • METHODS: Using methylation-specific polymerase chain reaction (MSP) the promoter methylation status of MAL was analyzed in 218 samples, including normal mucosa (n = 44), colorectal adenomas (n = 63), carcinomas (n = 65), and various cancer cell lines (n = 46).
  • Immunohistochemical analysis of MAL was done using normal colon mucosa samples (n = 5) and a tissue microarray with 292 colorectal tumors.
  • RESULTS: Bisulphite sequencing revealed that the methylation was unequally distributed within the MAL promoter and by MSP analysis a region close to the transcription start point was shown to be hypermethylated in the majority of colorectal carcinomas (49/61, 80%) as well as in adenomas (45/63, 71%).
  • CONCLUSION: Promoter hypermethylation of MAL was present in the vast majority of benign and malignant colorectal tumors, and only rarely in normal mucosa, which makes it suitable as a diagnostic marker for early colorectal tumorigenesis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / genetics. DNA Methylation. Membrane Transport Proteins / genetics. Myelin Proteins / genetics. Proteolipids / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2003 May 29;22(22):3463-71 [12776198.001]
  • [Cites] J Histochem Cytochem. 2003 May;51(5):665-74 [12704214.001]
  • [Cites] J Obstet Gynaecol Res. 2004 Feb;30(1):53-8 [14718022.001]
  • [Cites] Lancet. 2004 Apr 17;363(9417):1283-5 [15094274.001]
  • [Cites] Histol Histopathol. 2004 Jul;19(3):925-33 [15168355.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(7):1997-2001 [3494249.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):475-80 [1911187.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3455-60 [9699680.001]
  • [Cites] J Cell Biol. 1999 Apr 5;145(1):141-51 [10189374.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2029-33 [10232580.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):414-20 [10365903.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3730-40 [10446989.001]
  • [Cites] Gastroenterology. 2005 Jan;128(1):192-206 [15633136.001]
  • [Cites] Neoplasia. 2005 Feb;7(2):99-108 [15802015.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Gastroenterology. 2006 Sep;131(3):797-808 [16952549.001]
  • [Cites] Cell Oncol. 2006;28(5-6):259-72 [17167179.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Jan;5(1):111-7 [17161655.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1631-2; author reply 1632 [17408629.001]
  • [Cites] Dis Colon Rectum. 2007 Oct;50(10):1618-26; discussion 1626-7 [17762966.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5849-52 [8261392.001]
  • [Cites] Nucleic Acids Res. 1994 Aug 11;22(15):2990-7 [8065911.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):808-11 [9041175.001]
  • [Cites] DNA Cell Biol. 1997 Mar;16(3):245-55 [9115633.001]
  • [Cites] Endocrinology. 1998 Apr;139(4):2077-84 [9528996.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6870-5 [9618505.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4366-71 [10969779.001]
  • [Cites] Lab Invest. 2001 Feb;81(2):217-29 [11232644.001]
  • [Cites] Nucleic Acids Res. 2001 Jul 1;29(13):E65-5 [11433041.001]
  • [Cites] Br J Cancer. 2002 Feb 12;86(4):574-9 [11870540.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):820-9 [12610180.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1747-57 [14652236.001]
  • (PMID = 18346269.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MAL protein, human; 0 / Membrane Transport Proteins; 0 / Myelin Proteins; 0 / Myelin and Lymphocyte-Associated Proteolipid Proteins; 0 / Proteolipids
  • [Other-IDs] NLM/ PMC2292685
  •  go-up   go-down


86. Campos FG, Valarini R: Evolution of laparoscopic colorectal surgery in Brazil: results of 4744 patients from the national registry. Surg Laparosc Endosc Percutan Tech; 2009 Jun;19(3):249-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolution of laparoscopic colorectal surgery in Brazil: results of 4744 patients from the national registry.
  • BACKGROUND: Since its introduction, laparoscopic colorectal surgery has raised intense debate and controversies regarding its safety and effectiveness.
  • METHODS: This multicentric registry reports the experience of 28 Brazilian surgical teams specializing in laparoscopic colorectal surgery.
  • Benign diseases were diagnosed in 2356 patients (49.6%).
  • Two thousand three hundred and eighty-nine (50.4%) malignant tumors were operated upon, and histologic classification showed 2347 (98%) adenocarcinomas, 30 (0.6%) spinocelular carcinomas, and 12 (0.2%) other histologic types.
  • Tumor recurrence rate was 16.3% among patients followed more than 1 year.
  • Compared with other registries, there was a 75% increase in the number of groups performing laparoscopic colorectal surgery and a decrease in conversions (from 10.5% to 5.5%) and mortality (from 1.5% to 0.9%) rates.
  • (2) operative indications for benign and malignant diseases were similar, and diverticular disease of the colon comprised 40% of the benign ones;.

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542856.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. De Chiara L, Rodríguez-Piñeiro AM, Rodríguez-Berrocal FJ, Cordero OJ, Martínez-Ares D, Páez de la Cadena M: Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas. BMC Cancer; 2010;10:333
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas.
  • BACKGROUND: Serum CD26 (sCD26) levels were previously found diminished in colorectal cancer (CRC) patients compared to healthy donors, suggesting its potential utility for early diagnosis.
  • Patients were diagnosed as having no colorectal pathology, non-inflammatory or inflammatory bowel disease, polyps (hyperplastic, non-advanced and advanced adenomas) or CRC.
  • RESULTS: At a 460 ng/mL cut-off, the sCD26 has a sensitivity and specificity of 81.8% (95% CI, 64.5-93.0%) and 72.3% (95% CI, 65.0-77.2%) for CRC regarding no or benign colorectal pathology.
  • CONCLUSIONS: Our preliminary results show that measurement of the sCD26 is a non-invasive and reasonably sensitive assay, which could be combined with others such as the faecal occult blood test for the early diagnosis and screening of CRC and advanced adenomas.
  • [MeSH-major] Adenoma / blood. Biomarkers, Tumor / blood. Colorectal Neoplasms / blood. Dipeptidyl Peptidase 4 / blood. Polyps / metabolism. Polyps / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Colonoscopy. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Sensitivity and Specificity. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Nov;83(9):1139-46 [11027426.001]
  • [Cites] Aliment Pharmacol Ther. 2010 Feb 15;31(4):523-33 [19925498.001]
  • [Cites] N Engl J Med. 2001 Aug 23;345(8):555-60 [11529208.001]
  • [Cites] Scand J Immunol. 2001 Sep;54(3):249-64 [11555388.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1165-8 [11700264.001]
  • [Cites] Am J Gastroenterol. 2002 Dec;97(12):3186-94 [12492209.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):608-14 [12612899.001]
  • [Cites] Eur J Cell Biol. 2003 Feb;82(2):53-73 [12647932.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):259-69 [12785000.001]
  • [Cites] Dis Markers. 2003-2004;19(6):267-72 [15258327.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] N Engl J Med. 1993 May 13;328(19):1365-71 [8474513.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] N Engl J Med. 1996 Jan 18;334(3):155-9 [8531970.001]
  • [Cites] Lancet. 1996 Nov 30;348(9040):1472-7 [8942775.001]
  • [Cites] N Engl J Med. 2004 Dec 23;351(26):2704-14 [15616205.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):66-73 [16012935.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6550-7 [16166432.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):343-50 [16454841.001]
  • [Cites] Cancer. 2006 Oct 1;107(7):1624-33 [16933324.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5600-5 [17575123.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 3;99(19):1462-70 [17895475.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1357-67 [18033685.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1349-54 [18316554.001]
  • [Cites] CA Cancer J Clin. 2008 May-Jun;58(3):161-79 [18443206.001]
  • [Cites] World J Gastroenterol. 2008 May 7;14(17):2662-9 [18461651.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1570-95 [18384785.001]
  • [Cites] Am J Gastroenterol. 2008 Jun;103(6):1541-9 [18479499.001]
  • [Cites] Int J Colorectal Dis. 2008 Apr;23(4):383-7 [18193432.001]
  • [Cites] Int J Colorectal Dis. 2009 Mar;24(3):275-81 [18979105.001]
  • [Cites] BMC Bioinformatics. 2009;10:209 [19586526.001]
  • [Cites] Dis Markers. 2009;27(6):311-6 [20075514.001]
  • [Cites] Oncology. 2000 Nov;59(4):310-6 [11096343.001]
  • (PMID = 20584285.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.14.5 / Dipeptidyl Peptidase 4
  • [Other-IDs] NLM/ PMC2912863
  •  go-up   go-down


88. Wietfeldt ED, Thiele J: Malignancies of the anal margin and perianal skin. Clin Colon Rectal Surg; 2009 May;22(2):127-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Buschke-Lowenstein tumor, or giant condyloma acuminatum, is not always included because this lesion is technically benign, although it displays aggressive local invasive behavior that makes it difficult to manage.
  • Proper diagnosis requires a high index of suspicion on the part of the surgeon.
  • Innocent local irritations will resolve in a short time with appropriate therapy; those that persist must be biopsied for tissue diagnosis.
  • Wide local excision is the mainstay of treatment for early stage tumors as it preserves continence and obtains adequate local control.
  • Invasion and metastasis are relatively rare in this group of neoplasms; perianal Paget's disease has the highest risk of associated underlying neoplasm.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2008 Dec;51(12):1842-5 [18584248.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7 [17637368.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):427-31; discussion 431-2 [17430376.001]
  • [Cites] Br J Dermatol. 2007 Jan;156(1):11-21 [17199561.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):587-90 [11442599.001]
  • [Cites] Dis Colon Rectum. 1997 Oct;40(10):1187-94 [9336114.001]
  • [Cites] Br J Dermatol. 1995 Jun;132(6):970-2 [7662577.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • (PMID = 20436838.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780245
  • [Keywords] NOTNLM ; Anal margin cancer / diagnosis / local excision / radiation therapy / treatment options
  •  go-up   go-down


89. Chzhao AV, Kovalenko IuA, Chugunov AO, Novruzbekov MS: [Volume of surgical resection by liver focal lesions]. Khirurgiia (Mosk); 2010;(5):15-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Volume resection by malignant and benign liver lesions was defined, depending on size, localization, number of foci and functional liver reserve.
  • Postoperative lethality of patients with colorectal cancer metastases was 4.3%.
  • Method of surgical treatment depended directly on the tumor stage.
  • Overall and disease-free survival by colorectal cancer metastases was 35.1 and 22.4%, respectively.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / mortality. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Colorectal Neoplasms / mortality. Colorectal Neoplasms / secondary. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20559205.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


90. Crivello A, Giacalone A, Vaglica M, Scola L, Forte GI, Macaluso MC, Raimondi C, Di Noto L, Bongiovanni A, Accardo A, Candore G, Palmeri L, Verna R, Caruso C, Lio D, Palmeri S: Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma. Ann N Y Acad Sci; 2006 Nov;1089:98-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma.
  • Classic examples include Helicobacter pylori-associated gastric cancer, hepatocellular carcinoma, and inflammatory bowel disease-associated colorectal cancer.
  • As an example, IL-10-deficient mice develop severe atrophic gastritis and a chronic enterocolitis, developing colorectal cancer similar to human inflammatory bowel disease-associated neoplasia.
  • Animal experiments suggest that TGF-beta1 plays a biphasic role in carcinogenesis by protecting against the early formation of benign epithelial growths, but promoting a significant stimulation of tumor growth invasion and metastasis during tumor progression.
  • We assessed association of functional polymorphisms (-1082G/A; -592C/A) and TGF-beta1 (-509C/T; +869C/T) influencing the IL-10 production to colorectal cancer risk in a case-control study of 62 patients and 124 matched controls.
  • These results suggest that the +869C allele, responsible for a Leu-->Pro substitution in the signal peptide sequence of the TGF-beta1 protein, may have a predisposing role in the development of colorectal cancer.
  • [MeSH-major] Carcinoma / genetics. Colorectal Neoplasms / genetics. Genetic Predisposition to Disease. Transforming Growth Factor beta1 / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. L-Leucine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17261758.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta1; 130068-27-8 / Interleukin-10; 9DLQ4CIU6V / Proline; GMW67QNF9C / Leucine
  •  go-up   go-down


91. Ballian N, Liu SH, Brunicardi FC: Transcription factor PDX-1 in human colorectal adenocarcinoma: a potential tumor marker? World J Gastroenterol; 2008 Oct 14;14(38):5823-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcription factor PDX-1 in human colorectal adenocarcinoma: a potential tumor marker?
  • AIM: To examine the expression of pancreatic duodenal homeobox-1 (PDX-1) transcription factor in human colorectal cancer.
  • METHODS: RT-PCR, Western blotting, and immuno-histochemistry were performed to determine the expression pattern of transcription factor PDX-1 in primary colorectal tumor, hepatic metastasis, and benign colon tissue from a single patient.
  • Lower levels of PDX-1 were found to be present in the primary tumor, while normal colon tissue failed to express detectable levels of PDX-1.
  • Immunohistochemistry confirmed high metastasis PDX-1 expression, lower levels in the primary tumor, and the presence of only traces of PDX-1 in normal colon tissue.
  • CONCLUSION: These data argue for further evaluation of PDX-1 as a biomarker for colorectal cancer.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Colorectal Neoplasms / chemistry. Homeodomain Proteins / analysis. Liver Neoplasms / chemistry. Trans-Activators / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pol J Pathol. 2004;55(3):9-14 [15619975.001]
  • [Cites] Diabetes. 1999 May;48(5):1013-9 [10331405.001]
  • [Cites] World J Surg. 2005 Mar;29(3):334-8 [15706433.001]
  • [Cites] J Womens Health (Larchmt). 2007 Jan-Feb;16(1):57-65 [17324097.001]
  • [Cites] Histochem Cell Biol. 2007 Nov;128(5):445-55 [17851679.001]
  • [Cites] J Surg Res. 2008 Jan;144(1):8-16 [17583748.001]
  • [Cites] Gastroenterol Clin North Am. 2008 Mar;37(1):97-115, vii [18313542.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1570-95 [18384785.001]
  • [Cites] Pancreas. 2008 Aug;37(2):210-20 [18665085.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):169-74 [10900275.001]
  • [Cites] N Engl J Med. 2000 Nov 30;343(22):1603-7 [11096167.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1065-70 [11158595.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1118-26 [11350874.001]
  • [Cites] Gut. 2002 Sep;51(3):450-4 [12171973.001]
  • [Cites] Surgery. 2003 Aug;134(2):260-6 [12947327.001]
  • [Cites] Pancreas. 2004 Mar;28(2):109-20 [15028942.001]
  • [Cites] World J Surg. 2004 Aug;28(8):826-33 [15457366.001]
  • [Cites] N Engl J Med. 1993 May 13;328(19):1365-71 [8474513.001]
  • [Cites] J Biol Chem. 1994 May 27;269(21):15229-37 [7910823.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):586-92 [7677172.001]
  • [Cites] Genomics. 1996 Jun 1;34(2):270-1 [8661069.001]
  • [Cites] Lancet. 1996 Nov 30;348(9040):1467-71 [8942774.001]
  • [Cites] Lancet. 1996 Nov 30;348(9040):1472-7 [8942775.001]
  • [Cites] Drugs. 1997 Apr;53(4):593-607 [9098662.001]
  • [Cites] Diabetes. 1999 Mar;48(3):507-13 [10078550.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):476-87 [15689586.001]
  • (PMID = 18855980.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Homeodomain Proteins; 0 / RNA, Messenger; 0 / Trans-Activators; 0 / pancreatic and duodenal homeobox 1 protein
  • [Other-IDs] NLM/ PMC2751891
  •  go-up   go-down


92. Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta-Tselenis S, Giannopoulos A, Mantzoros CS: Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev; 2007 Feb;16(2):308-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Adiponectin, an adipocyte-secreted hormone with insulin-sensitizing effects, has been inversely associated with several hormonally dependent malignancies, including breast, endometrial, and colorectal cancer.
  • Few studies have examined serum adiponectin in relation to prostate cancer, and expression of adiponectin receptors has previously not been assessed in prostate tumors.
  • EXPERIMENTAL DESIGN: We collected plasma samples and covariate data in the context of a case-control study of 300 Greek men, including 75 prostate cancer cases, 75 patients with benign prostatic hyperplasia (BPH), and 150 healthy controls.
  • Malignant prostate tissue samples have reduced expression of adiponectin receptors as compared with benign prostate tissue.
  • [MeSH-major] Adiponectin / blood. Biomarkers, Tumor / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Neoplasms / metabolism. Receptors, Cell Surface / metabolism